1. Introduction {#sec1-ijms-20-01667}
===============

Fritillariae Thunbergii Bulbus (FTB) is also known as Zhe bei mu or Xiang bei mu in Chinese, Setsubaimo in Japanese and Jeolpaemo in Korean \[[@B1-ijms-20-01667]\]. Fritillariae Thunbergii belongs to the Fritillariae (Liliaceae) family and FTB has been widely used as an antitussive herb for thousands of years in China \[[@B2-ijms-20-01667]\]. Fritillariae Thunbergii is widely cultivated in the south-eastern coastal, south-central and eastern areas of China, such as Zhejiang, Jiangsu, Anhui and Hunan provinces \[[@B2-ijms-20-01667]\]. FTB is a significant traditional Chinese herb with bitter and cold properties, entering the Lung and Heart channels \[[@B2-ijms-20-01667]\]. It is generally prescribed as one of the ingredients of herbal formula, such as Danggui Beimu Kushen Wan (Chinese Angelica, Fritillaria and Flavescent Sophora Pill; DBKW) in traditional and contemporary clinical practice \[[@B3-ijms-20-01667],[@B4-ijms-20-01667]\]. Recently, investigating potential treatments from ancient records has been employed as a strategy to direct novel drug discovery \[[@B5-ijms-20-01667]\]. Modern studies that are recorded in the Zhong Yao Da Ci Dian (Great Compendium of Chinese Medicines) \[[@B6-ijms-20-01667]\] and Zhong Hua Ben Cao (Chinese Pharmacopoeia) \[[@B7-ijms-20-01667]\] indicated that the pharmacological effects of FTB include antitussive, tracheobronchial relaxation, anti-muscarinic, expectorant and pain suppression with a wide range of chemical constituents, such as peimine and peiminine. With the development of modern methodological approaches, an increasing number of new chemical constituents (e.g., frithunbol A and frithunbol B) \[[@B8-ijms-20-01667]\], and pharmacological effects (e.g., anti-cancer activity \[[@B9-ijms-20-01667]\] and neuroprotection \[[@B8-ijms-20-01667]\]) have been found in FTB. Therefore, there is a need to thoroughly review FTB from traditional and modern perspectives to assist further drug discovery. This study aimed to review traditional uses, phytochemical, pharmacodynamic, pharmacokinetic and toxicity characteristics of FTB and provide comprehensive and evidence-based information to practitioners and researchers.

2. Traditional Uses of FTB {#sec2-ijms-20-01667}
==========================

The Zhong Hua Yi Dian (Encyclopedia of Traditional Chinese Medicine; ZHYD) CD-ROM, containing 1156 ancient books, was searched to identify potential classic literature of FTB \[[@B10-ijms-20-01667]\]. FTB was first documented in the book Ben Cao Hui Yan (BCHY, Discourse on Herbal Medicine, NI Zhumo, 1624, Ming Dynasty), with its actions described as breaking blood and detoxication. In addition, five classic books, including Ben Cao Zheng Yao (Evidence of Materia Medica, LI Zhongzi, 1673, Qing dynasty), Ben Jing Feng Yuan (Doctrine of Origin, ZHANG Lu, 1695, Qing dynasty), Ben Cao Gang Mu Shi Yi (Supplement to the Compendium of Materia Medica, ZHAO Xuemin, 1765, Qing dynasty), Ben Cao Bian Du (Simple Materia Medica, ZHANG Bingcheng, 1887, Qing dynasty) and Ben Cao Zheng Yi (Merits of Herbal Medicine, ZHANG Shanlei, 1920, Republic of China), specified that the unique actions of FTB were to clear the Lung and calm the Liver, disperse the Lung-Qi to relieve depression, clear the Heart and reduce the heat, which were not found in other Fritillariae species, such as Fritillariae Cirrhosae Bulbus (Chuan bei mu) and Bulbus Bolbostemmatis Rhizoma (Tu Bei Mu). In summary, FTB acts to clear heat, resolve phlegm, relieve cough, remove toxicity and disperse abscesses and nodules. A number of herbal formulas containing FTB were identified. [Supplementary file 1](#app1-ijms-20-01667){ref-type="app"} presents some example formulas containing FTB as an ingredient in ZHYD. Herbal ingredients in [Supplementary file 1](#app1-ijms-20-01667){ref-type="app"} are listed as Chinese pinyin name as per the nomenclature list of commonly used Chinese herbal medicines published by the Chinese Medicine Board of Australia \[[@B11-ijms-20-01667]\]. Today, some of them are continuously used by practitioners in evidence-based Chinese medicine clinical practice, such as DBKW, Guang Bi Shu Zhan Tang (Throat Tuberculosis Decoction), Xiao Lei Wan (Eliminate Scrofula Pill), Xing Su Yin (Apricot Kernel and Perilla Leaf Decoction), Qing Jin Ning Sou Tang (Clear the Lung and Stop Cough Decoction), Tuo Li Pai Nong Tang (Support the Interior and Drain Pus Decoction), Ren Shen Bai Du San (Ginseng Powder to Overcome Toxin) and Xian Fang Huo Ming Yin (Sublime Formula for Sustaining Life).

In terms of the indications of FTB, Ben Cao Zheng (Orthodox Materia Medica, ZHANG Jiebin, 1624, Ming dynasty) recorded that it could be used for a number of conditions, including lung abscess, lung atrophy, cough, dyspnea, hematemesis, epistaxis, hematochezia, hematuria, jaundice, difficult urination, pharyngitis, hemorrhoid, anal fistula, acute mastitis, scrofula and any furuncles, carbuncle, abscess and other inflammation and swelling. Ben Cao Cong Xin (New Revised Materia Medica, WU Yiluo, 1751, Qing dynasty) claimed that FTB could be utilized for patients with flu induced by wind-phlegm. Ben Cao Gang Mu Shi Yi provided further descriptions that the indications of FTB could be extended to any respiratory disorders which are due to wind-fire and phlegm. As shown in [Supplementary file 1](#app1-ijms-20-01667){ref-type="app"}, those formulas had been widely used in various disciplines along with the development of Chinese medicine, including otorhinolaryngology, ophthalmology, external medicine, gynecology, obstetrics, galactophore and infectious diseases.

3. Modern Exploration of FTB {#sec3-ijms-20-01667}
============================

The following seven English and four Chinese electronic databases were searched from their respective inceptions to 2 November 2018: PubMed, EMBASE, CINAHL, Science Direct, Scopus, ProQuest, Allied and Complementary Medicine Database, CNKI, CQVIP, Wanfangdata and CBM. Keywords used to identify potential studies included: Zhe bei mu and its English, Latin, Japanese, Korean, botanical and pharmaceutical names and their synonyms. The reference list of review articles was screened manually for potential studies.

Original experimental studies on phytochemistry and pharmacology, or the studies containing phytochemical or pharmacological tests, published in English or Chinese, were considered for inclusion, regardless of the type of experimental studies (e.g., in vivo and in vitro). The studies were included if they investigated a single raw herb with species and specific medicinal parts of FTB listed in the Pharmacopoeia of the People's Republic of China. The literature was excluded if they are review articles or do not include original phytochemical or pharmacological studies, or did not use a raw herb with appropriate species or medicinal parts of FTB, or directly used chemical compounds instead of a raw herb as the research material, or published in a non-English or non-Chinese language.

One reviewer (HL) screened the searched literature and extracted the following data to a predesigned Excel form: Compound name, molecular formula, molecular weight, molecular structure and analysis methods for phytochemical studies; and compound name, study type, characteristics of sample, interventions, duration, outcome measures, main results for pharmacological studies. Corresponding molecular structures were further searched in the PubChem database to obtain the PubChem CID/SID number. The molecular structures that could not be found in PubChem were drawn manually using the software ChemDraw. All included studies were divided into two groups: Studies reporting a voucher number (SRV) and studies not reporting voucher number (SNRV). A voucher specimen number is one of the most significant requirements for phytological studies, since it ensures the reliability of botanical taxon and the repeatability of published studies \[[@B12-ijms-20-01667],[@B13-ijms-20-01667]\]. The data was checked and confirmed by the second reviewer (ML). When any discrepancies between the two reviewers occurred, they were discussed with the third party (AY) to resolve the issues. A descriptive summary was performed to obtain the characteristics of the extracted data.

A total of 9706 experimental studies were identified adhering to the search strategies mentioned above. Eighty-three studies meeting the inclusion criteria were included for analysis, including 63 phytochemical studies \[[@B8-ijms-20-01667],[@B14-ijms-20-01667],[@B15-ijms-20-01667],[@B16-ijms-20-01667],[@B17-ijms-20-01667],[@B18-ijms-20-01667],[@B19-ijms-20-01667],[@B20-ijms-20-01667],[@B21-ijms-20-01667],[@B22-ijms-20-01667],[@B23-ijms-20-01667],[@B24-ijms-20-01667],[@B25-ijms-20-01667],[@B26-ijms-20-01667],[@B27-ijms-20-01667],[@B28-ijms-20-01667],[@B29-ijms-20-01667],[@B30-ijms-20-01667],[@B31-ijms-20-01667],[@B32-ijms-20-01667],[@B33-ijms-20-01667],[@B34-ijms-20-01667],[@B35-ijms-20-01667],[@B36-ijms-20-01667],[@B37-ijms-20-01667],[@B38-ijms-20-01667],[@B39-ijms-20-01667],[@B40-ijms-20-01667],[@B41-ijms-20-01667],[@B42-ijms-20-01667],[@B43-ijms-20-01667],[@B44-ijms-20-01667],[@B45-ijms-20-01667],[@B46-ijms-20-01667],[@B47-ijms-20-01667],[@B48-ijms-20-01667],[@B49-ijms-20-01667],[@B50-ijms-20-01667],[@B51-ijms-20-01667],[@B52-ijms-20-01667],[@B53-ijms-20-01667],[@B54-ijms-20-01667],[@B55-ijms-20-01667],[@B56-ijms-20-01667],[@B57-ijms-20-01667],[@B58-ijms-20-01667],[@B59-ijms-20-01667],[@B60-ijms-20-01667],[@B61-ijms-20-01667],[@B62-ijms-20-01667],[@B63-ijms-20-01667],[@B64-ijms-20-01667],[@B65-ijms-20-01667],[@B66-ijms-20-01667],[@B67-ijms-20-01667],[@B68-ijms-20-01667],[@B69-ijms-20-01667],[@B70-ijms-20-01667],[@B71-ijms-20-01667],[@B72-ijms-20-01667],[@B73-ijms-20-01667],[@B74-ijms-20-01667],[@B75-ijms-20-01667]\] and 30 pharmacological studies \[[@B8-ijms-20-01667],[@B9-ijms-20-01667],[@B17-ijms-20-01667],[@B27-ijms-20-01667],[@B33-ijms-20-01667],[@B45-ijms-20-01667],[@B49-ijms-20-01667],[@B56-ijms-20-01667],[@B59-ijms-20-01667],[@B73-ijms-20-01667],[@B75-ijms-20-01667],[@B76-ijms-20-01667],[@B77-ijms-20-01667],[@B78-ijms-20-01667],[@B79-ijms-20-01667],[@B80-ijms-20-01667],[@B81-ijms-20-01667],[@B82-ijms-20-01667],[@B83-ijms-20-01667],[@B84-ijms-20-01667],[@B85-ijms-20-01667],[@B86-ijms-20-01667],[@B87-ijms-20-01667],[@B88-ijms-20-01667],[@B89-ijms-20-01667],[@B90-ijms-20-01667],[@B91-ijms-20-01667],[@B92-ijms-20-01667],[@B93-ijms-20-01667],[@B94-ijms-20-01667]\], as 10 studies reported both phytochemical and pharmacological effects of FTB \[[@B8-ijms-20-01667],[@B17-ijms-20-01667],[@B27-ijms-20-01667],[@B33-ijms-20-01667],[@B45-ijms-20-01667],[@B49-ijms-20-01667],[@B56-ijms-20-01667],[@B59-ijms-20-01667],[@B73-ijms-20-01667],[@B75-ijms-20-01667]\]. [Figure 1](#ijms-20-01667-f001){ref-type="fig"} details the selection process of included studies.

3.1. Phytochemistry of FTB {#sec3dot1-ijms-20-01667}
--------------------------

A total of 134 chemical constituents were identified, including 26 alkaloids (A1--A26), 29 compounds found in essential oils (B1--B29), 13 diterpenoids (C1--C13), two carbohydrates (D1--D2), two sterols (E1--E2), 18 amino acids (F1--F18), six nucleosides (G1--G6), four nucleobases (H1--H4), four fatty acids (I1--I4), three lignans (J1--J3), and 27 elements (K1--K27). [Table 1](#ijms-20-01667-t001){ref-type="table"} details the characteristics of chemical constituents isolated from FTB.

Within 63 included phytochemical studies, there are 17 SRV (47 constituents isolated) \[[@B8-ijms-20-01667],[@B14-ijms-20-01667],[@B21-ijms-20-01667],[@B26-ijms-20-01667],[@B33-ijms-20-01667],[@B38-ijms-20-01667],[@B43-ijms-20-01667],[@B44-ijms-20-01667],[@B50-ijms-20-01667],[@B56-ijms-20-01667],[@B58-ijms-20-01667],[@B60-ijms-20-01667],[@B62-ijms-20-01667],[@B63-ijms-20-01667],[@B70-ijms-20-01667],[@B71-ijms-20-01667],[@B72-ijms-20-01667]\] and 46 SNRV (118 constituents isolated) \[[@B15-ijms-20-01667],[@B16-ijms-20-01667],[@B17-ijms-20-01667],[@B18-ijms-20-01667],[@B19-ijms-20-01667],[@B20-ijms-20-01667],[@B22-ijms-20-01667],[@B23-ijms-20-01667],[@B24-ijms-20-01667],[@B25-ijms-20-01667],[@B26-ijms-20-01667],[@B27-ijms-20-01667],[@B28-ijms-20-01667],[@B29-ijms-20-01667],[@B30-ijms-20-01667],[@B31-ijms-20-01667],[@B32-ijms-20-01667],[@B34-ijms-20-01667],[@B35-ijms-20-01667],[@B36-ijms-20-01667],[@B37-ijms-20-01667],[@B39-ijms-20-01667],[@B40-ijms-20-01667],[@B41-ijms-20-01667],[@B42-ijms-20-01667],[@B45-ijms-20-01667],[@B46-ijms-20-01667],[@B47-ijms-20-01667],[@B48-ijms-20-01667],[@B49-ijms-20-01667],[@B51-ijms-20-01667],[@B52-ijms-20-01667],[@B53-ijms-20-01667],[@B54-ijms-20-01667],[@B55-ijms-20-01667],[@B57-ijms-20-01667],[@B59-ijms-20-01667],[@B61-ijms-20-01667],[@B64-ijms-20-01667],[@B65-ijms-20-01667],[@B66-ijms-20-01667],[@B69-ijms-20-01667],[@B73-ijms-20-01667],[@B74-ijms-20-01667],[@B75-ijms-20-01667]\]. Thirty-one chemical constituents were identified in both SRV and SNRV groups, including nine alkaloids (A1, A2, A5, A6, A7, A9, A11, A14 and A15), four nucleosides (G1-G4), one nucleobases (I1), and 17 elements (K1, K2, K6-K12, K14, K16, K17, K19, K20, K22, K25 and K27). In terms of the molecular structures, 117 chemical constituents were found in the PubChem database that refers to the corresponding PubChem CID/SID, however, 17 constituents were not available in PubChem. Amount of the 17 chemical components, 14 of the molecular structures (A4, A11, A16, A17, A27, A30-A33, C2-C4, C9 and C12) could be found in the included studies and three of them (A10, A22 and D1) could not be found anywhere. Details of the 14 molecular structures were presented in [Figure 2](#ijms-20-01667-f002){ref-type="fig"}.

### 3.1.1. Alkaloids {#sec3dot1dot1-ijms-20-01667}

Current studies mainly focused on the alkaloids which are the fundamental components of FTB \[[@B34-ijms-20-01667]\]. Among 26 isolated alkaloids in FTB, 0.080% of peimine (A1) and peiminine (A2) used for identification and quality control as listed in the Pharmacopeia of People's Republic of China \[[@B2-ijms-20-01667]\]. These two compounds were first isolated in 1960 using the paper partition chromatography method \[[@B46-ijms-20-01667]\] and then they were consistently found by over 40 research teams using more than 20 different methods from 1960 to 2018 \[[@B8-ijms-20-01667],[@B17-ijms-20-01667],[@B18-ijms-20-01667],[@B20-ijms-20-01667],[@B21-ijms-20-01667],[@B22-ijms-20-01667],[@B23-ijms-20-01667],[@B24-ijms-20-01667],[@B26-ijms-20-01667],[@B27-ijms-20-01667],[@B28-ijms-20-01667],[@B29-ijms-20-01667],[@B31-ijms-20-01667],[@B32-ijms-20-01667],[@B33-ijms-20-01667],[@B36-ijms-20-01667],[@B37-ijms-20-01667],[@B38-ijms-20-01667],[@B39-ijms-20-01667],[@B41-ijms-20-01667],[@B42-ijms-20-01667],[@B44-ijms-20-01667],[@B45-ijms-20-01667],[@B47-ijms-20-01667],[@B48-ijms-20-01667],[@B49-ijms-20-01667],[@B51-ijms-20-01667],[@B56-ijms-20-01667],[@B57-ijms-20-01667],[@B59-ijms-20-01667],[@B60-ijms-20-01667],[@B63-ijms-20-01667],[@B70-ijms-20-01667],[@B72-ijms-20-01667],[@B73-ijms-20-01667],[@B75-ijms-20-01667]\]. The in vivo and in vitro experimental studies identified the biological activities of peimine (A1) and peiminine (A2), such as anti-cancer activity \[[@B49-ijms-20-01667]\], tracheobronchial relaxation \[[@B17-ijms-20-01667]\], anti-muscarinic activity \[[@B75-ijms-20-01667]\], anti-inflammatory activity \[[@B33-ijms-20-01667],[@B88-ijms-20-01667]\], and pain suppression \[[@B88-ijms-20-01667]\], which indicates they may have great potential in clinical practice. In addition, some isomers were also reported, including peimine (A1) \[[@B33-ijms-20-01667]\], zhebeinine (A3) \[[@B68-ijms-20-01667]\] and isoverticine (A7) \[[@B56-ijms-20-01667]\] with the same molecular formula C~27~H~45~NO~3~, peiminine (A2) \[[@B21-ijms-20-01667]\], zhebeinone (A4) \[[@B65-ijms-20-01667]\] and suchengbeisine (A8) \[[@B33-ijms-20-01667]\] with the same molecular formula C~27~H~43~NO~3~, ebeiedine (A5) \[[@B33-ijms-20-01667]\], puqiedine (A15) \[[@B72-ijms-20-01667]\], N-demethylpuqietinon (A19) \[[@B73-ijms-20-01667]\] and eduardinine (A25) \[[@B8-ijms-20-01667]\] with the same molecular formula C~27~H~45~NO~2~, ebeiedinone (A6) \[[@B56-ijms-20-01667]\], puqiedinone (A14) \[[@B72-ijms-20-01667]\], eduardine (A16) \[[@B66-ijms-20-01667]\] and zhebeirine (A17) \[[@B66-ijms-20-01667]\] with the same molecular formula C~27~H~43~NO~2~, and frithunbol B (A24) \[[@B8-ijms-20-01667]\] and 3β-hydroxy-5α-jervanin-12-en-6-one (A26) \[[@B8-ijms-20-01667]\] with the same molecular formula C~27~H~42~NO~3~. Another two new steroidal alkaloids were isolated and identified in 2018 \[[@B8-ijms-20-01667]\]. They are the colorless gum called frithunbol A (A23) and frithunbol B (A24) with the structures 5α-cevanin-13-ene-3β,6α,16β-triol-18-one and 3β-hydroxy-5α-jerv-12-en-6-one respectively, presented in [Figure 2](#ijms-20-01667-f002){ref-type="fig"}. Frithunbol B (A24) could reduce nitric oxide (NO) in vitro and it may possess neuroprotective activity \[[@B8-ijms-20-01667]\].

### 3.1.2. Compounds from Essential Oils {#sec3dot1dot2-ijms-20-01667}

A total of 29 compounds found in essential oils in FTB were investigated in two recent experimental studies using the gas chromatography--mass spectrometry method. One study reported 15 of them, including δ-elemene (B1), δ-selinene (B2), tetradecanoic acid (B3), pentadecanoic acid (B4), hexadecanoic acid, methyl ester (B5), 9-hexadecenoic acid (B6), n-hexadecanoic acid (B7), kaur-15-ene (B8), heptadecanoic acid (B9), kaurene (B10), 9,12-octadecadienoic acid (Z,Z)-, methyl ester (B11), 9-tetradecenal, (Z)- (B12), 9,12-octadecadienoic acid, methyl ester, (E, E)- (B13), oleic acid (B14), and linoleic acid, ethyl ester (B15) \[[@B16-ijms-20-01667]\]. Among these 15 constituents, n-hexadecanoic acid (B7), 9,12-octadecadienoic acid, methyl ester, (E, E)- (B13), and oleic acid (B14) were the three primary compounds found in essential oils in FTB accounting for 53.46%, 26.96% and 9.34% respectively. Another study also found hexadecanoic acid, methyl ester (B5), and reported another 14 chemical compounds, including butylated hydroxytoluene (B16), L-(+)-Ascorbic acid 2,6-dihexadecanoate (B17), ethyl 9-hexadecenoate (B18), hexadecanoic acid, ethyl ester (B19), 1H-naphtho \[2,1-B\] pyran, 3-ethenyldodecahydro-3,4a,7,7,10a-pentamethyl- (B20), kaur-16-ene (B21), 9,11-octadecadienoic acid, methyl ester, (E, E)- (B22), 9,12-octadecadienoic acid (B23), linoleic acid, ethyl ester (B24), octadecanoic acid, ethyl ester (B25), 2(1H)-phenanthrenone, 3,4,4a,4b,5,6,7,8,10,10a-decahydro-1,1,4a,7,7-pentamethyl, \[4aR-(4a.α., 4b.β.,10a.β.)\]- (B26), 3-methyleneandrostan-17-ol (B27), androst-4-En-3-one, 17-hydroxy-, (17.β.) (B28), and podocarp-7-en-3.β.-ol, 13.β.-methyl-13-vinyl- (B29) \[[@B25-ijms-20-01667]\]. The latter study stated the proportion of four main compounds found in essential oils: Linoleic acid, ethyl ester (B24; 36.93%), kaur-16-ene (B21; 22.85%), hexadecanoic acid, methyl ester (B5; 10.67%), and 3-methyleneandrostan-17-ol (B27; 10.59%). However, the proportion of hexadecanoic acid, methyl ester (B5) in the former study was only 0.6% \[[@B25-ijms-20-01667]\]. It is worth noting that different compounds from essential oils with different proportions from FTB have been identified, due to the different isolation methods. The former study soaked FTB powders for 12 h and distilled it for 10 h \[[@B16-ijms-20-01667]\] whereas the soak time and distillation time in the later study were one hour and five hours respectively \[[@B25-ijms-20-01667]\]. Further studies should consider utilizing the appropriate isolation method to achieve selective isolation of target compounds. However, at the current stage, there is no solid evidence to identify which isolation method is better.

### 3.1.3. Diterpenoids {#sec3dot1dot3-ijms-20-01667}

Two studies conducted by the same Japanese research team in 1984 focused on the diterpenoids in FTB \[[@B34-ijms-20-01667],[@B35-ijms-20-01667]\]. Thirteen diterpenoids were identified using the nuclear magnetic resonance methods (1HNMR and 13CNMR), including isopimaran-19-ol (C1), isopimaran-19-oic acid, methyl ester (C2), ent-kauran-16β, 17-diol (C3), ent-kauran-16α, 17-diol (C4), ent-16β, 17-epoxy-kaurane (C5), ent-16α-methoxy-kauran-17-ol (C6), ent-kaur-15-en-17-ol (C7), trans-communol (C8), trans-comminic acid, methyl ester (C9), ent-17-norkauran-16-one (C10), ent-15β,16-epoxy-kauran-17-ol (C11), ent-16β-hydroxy-kauran-17-yl ent-kaur-15-en-17-oate (C12), and ent-(16S)-atisan-13, 17-oxide (C13) \[[@B34-ijms-20-01667],[@B35-ijms-20-01667]\]. However, no further studies, after 1984, were found on the investigation of the diterpenoids or the specific diterpenoids identified from FTB. As diterpenoids in other Chinese herbs may perform diverse biological activities, such as anti-cancer activity \[[@B95-ijms-20-01667]\], anti-inflammatory activity \[[@B96-ijms-20-01667]\] and antioxidative activity \[[@B97-ijms-20-01667]\], further studies which focus attention on diterpenoids in FTB may be important.

### 3.1.4. Nucleosides {#sec3dot1dot4-ijms-20-01667}

Three studies identified six nucleosides from FTB using three different methods (LC-ESI-MSn \[[@B70-ijms-20-01667]\], HPLC-UV-ESI/MS \[[@B70-ijms-20-01667]\] and HPLC \[[@B64-ijms-20-01667],[@B71-ijms-20-01667]\]), including uridine (G1), guanosine (G2), adenosine (G3), thymidine (G4), cytidine (G5), and inosine (G6). One of the studies highlighted that the content of nucleosides in FTB could be used as an index for the identification and quality control of FTB \[[@B64-ijms-20-01667]\]. However, to date, none of the included studies evaluated the pharmacological activities of nucleosides isolated from FTB. As the basic building-block of DNA and RNA, nucleosides from other plants possess many biological activities, such as anti-cancer activity \[[@B98-ijms-20-01667]\], antibacterial activity \[[@B99-ijms-20-01667]\], and antiviral activity \[[@B100-ijms-20-01667]\]. It is worth investigating nucleosides in FTB for novel drug discovery.

### 3.1.5. Elements {#sec3dot1dot5-ijms-20-01667}

A total of 27 elements were found for identification and quality control purposes \[[@B14-ijms-20-01667],[@B15-ijms-20-01667],[@B40-ijms-20-01667],[@B43-ijms-20-01667],[@B52-ijms-20-01667],[@B53-ijms-20-01667],[@B55-ijms-20-01667],[@B58-ijms-20-01667],[@B61-ijms-20-01667],[@B62-ijms-20-01667],[@B74-ijms-20-01667]\]. Eight of them are trace elements that may have vital biological activities in the human body, including cobalt, copper, iron, manganese, molybdenum, sulfur, selenium and zinc \[[@B14-ijms-20-01667],[@B15-ijms-20-01667],[@B40-ijms-20-01667],[@B43-ijms-20-01667],[@B52-ijms-20-01667],[@B54-ijms-20-01667],[@B55-ijms-20-01667],[@B58-ijms-20-01667],[@B61-ijms-20-01667],[@B62-ijms-20-01667],[@B74-ijms-20-01667]\]. Another six trace elements without any known biological activities were identified in FTB, including arsenic, cadmium, chromium, mercury, nickel and lead \[[@B14-ijms-20-01667],[@B15-ijms-20-01667],[@B40-ijms-20-01667],[@B43-ijms-20-01667],[@B55-ijms-20-01667],[@B58-ijms-20-01667],[@B61-ijms-20-01667],[@B62-ijms-20-01667],[@B74-ijms-20-01667]\]. They have toxic activities that may damage the lipids, proteins, enzymes and DNA even in low dose \[[@B101-ijms-20-01667]\]. All the toxic elements in the included studies were under the maximum limited level listed in the Pharmacopeia of the People's Republic of China \[[@B14-ijms-20-01667],[@B15-ijms-20-01667],[@B40-ijms-20-01667],[@B43-ijms-20-01667],[@B52-ijms-20-01667],[@B53-ijms-20-01667],[@B55-ijms-20-01667],[@B58-ijms-20-01667],[@B61-ijms-20-01667],[@B62-ijms-20-01667],[@B74-ijms-20-01667]\].

### 3.1.6. Other Constituents {#sec3dot1dot6-ijms-20-01667}

Apart from above chemical components, 33 chemical compounds belonging to six categories were isolated and identified, which are used for identification, as well as quality control, including two carbihydrates (β-[d]{.smallcaps}-glucose4-1β-[d]{.smallcaps}-galactose (D1) and sucrose (D2)) \[[@B19-ijms-20-01667]\], two sterols (β-sitosterol (E1) and daucosterol (E2)) \[[@B68-ijms-20-01667]\], 18 amino acids (glycine (F1), leucine (F2), methionine (F3), tyrosine (F4), histidine (F5), threonine (F6), alanine (F7), isoleucine (F8), tryptophan (F9), cystine (F10), lysine (F11), aspartic acid (F12), valine (F13), phenylalanine (F14), proline (F15), serine (F16), glutamic acid (F17) and arginine (F18)) \[[@B64-ijms-20-01667]\], four nucleobases (adenine (H1), hypoxanthine (H2), uracil (H3) and thymine (H4)) \[[@B64-ijms-20-01667],[@B70-ijms-20-01667]\], four fatty acids (vernolic acid (I1), 2-monopalmitin (I2), 13(R)-hydroxy-octadeca-(9Z,11E,15Z)-trien-oic acid (I3) and picropodophyllotoxin (I4)) \[[@B67-ijms-20-01667],[@B73-ijms-20-01667]\], and three lgnans (octahydrocurcumin (J1), zhebeiresinol (J2) and sauriol B (J3)) \[[@B30-ijms-20-01667],[@B73-ijms-20-01667]\].

3.2. Pharmacology of FTB {#sec3dot2-ijms-20-01667}
------------------------

There are 23 studies focused on the pharmacological effects of FTB, including anti-cancer, tracheobronchial relaxation, antitussive, expectorant, anti-muscarinic, anti-inflammation, anti-thyroid, regulation of blood rheology, antiulcer, anti-diarrhea, pain suppression, antioxidation and neuroprotection ([Figure 3](#ijms-20-01667-f003){ref-type="fig"}). Characteristics of the 23 included pharmacological effects are summarized in [Table 2](#ijms-20-01667-t002){ref-type="table"}.

### 3.2.1. Anti-Cancer Effect {#sec3dot2dot1-ijms-20-01667}

Cancer is one of the most life-threatening conditions with high morbidity and mortality in the world \[[@B102-ijms-20-01667]\]. However, the therapeutic effects of conventional medicine are unsatisfactory, due to many adverse effects, such as fatigue, nausea and vomiting \[[@B103-ijms-20-01667]\]. Increasingly, natural products have been identified with anti-cancer activity, which may be associated with better therapeutic effects and less adverse effects \[[@B104-ijms-20-01667],[@B105-ijms-20-01667]\]. Four included studies indicated that FTB had anti-cancer effect \[[@B9-ijms-20-01667],[@B49-ijms-20-01667],[@B80-ijms-20-01667],[@B91-ijms-20-01667]\]. Three of them investigated the multidrug resistance (MDR) reversal activity of FTB on human lung adenocarcinoma parental cells A549 \[[@B80-ijms-20-01667]\], human hepatocellular carcinoma cell line HepG2 \[[@B9-ijms-20-01667]\], and human breast carcinoma cells MCF-7 \[[@B49-ijms-20-01667]\]. Li and colleagues reported that the total alkaloids of FTB may have the MDR reversal activity on A549/cisplatin (A549/DDP) cells \[[@B80-ijms-20-01667]\]. Specifically, the 50% inhibitory concentration (IC50) of FTB extract in vitro was 141 ± 5 mg/L (A549 cells) and 298 ± 22 mg/L (A549/DDP cells) while the IC50 DDP plus FTB (9 mg/L) and DDP alone on A549/DDP cells was 14.06 ± 3.72 mg/L and 0.79 ± 0.14 mg/L respectively after 72-h intervention. The reversal fold (RF) of FTB to DDP on A549/DDP cells was 17.80, higher than other reversal agents, such as cyclosporine A (10.16) and tetrandrine (14.05). The tumor inhibitory rate of DDP plus FTB (2 mg/kg) was 67.4%, higher than DDP alone (49.9%). The expressions of MDR1 mRNA and P-glycoprotein (P-gp) were significantly decreased by FTB extract. Similar results on the expression of P-gp were also reported by another research team in China \[[@B9-ijms-20-01667]\]. They used the Calcein-AM Kit to identify potential P-gp inhibitors. The results showed that alkaloids and nucleoside in FTB significantly restricted the efflux activity of P-gp in a dosage-dependent manner. Furthermore, Tong specified that peimine (A1) and peiminine (A2) were the reversal agents in FTB that reversed the MDR of adriamycin or paclitaxel in MCF7/A cells. The RF of peimine (A1) plus adriamycin or paclitaxel and peiminine (A2) plus adriamycin or paclitaxel was 8.17, 4.57, 3.30 and 3.73 respectively after 48-h treatment. In addition, direct anti-cancer activity was also detected by in vitro and In vivo studies in one included study \[[@B91-ijms-20-01667]\]. The researchers believed that the FTB aqueous extract (75 mg/mL) inhibited the human lung adenocarcinoma parental cells LM2 with dosage dependence and the apoptosis rate was increased over time (24 h: 5.7 ± 0.91%; 48 h: 11.7 ± 1.07%). In vivo studies revealed that the tumor inhibitory rate of FTB aqueous extract (1.6 g/kg) was 33.33%. Concurrently, the same dose of FTB aqueous extract significantly reduced the number of metastases in mice (5.7 ± 1.72), compared to the control groups (7.3 ± 2.2) \[[@B91-ijms-20-01667]\]. FTB, especially peimine (A1) and peiminine (A2), seems to have both direct and indirect anti-cancer effects evidenced by inhibiting the growth of tumor cells, as well as reversing the MDR of conventional chemotherapy drugs, such as DDP, adriamycin and paclitaxel \[[@B9-ijms-20-01667],[@B49-ijms-20-01667],[@B80-ijms-20-01667],[@B91-ijms-20-01667]\]. Nonetheless, existing evidence is not sufficient to elucidate its mechanisms of actions on lung, liver or breast cancer. Therefore, more in vitro and In vivo studies are needed on lung, liver, breast and other cancers to thoroughly investigate its direct and indirect anti-cancer activity in the future.

### 3.2.2. Tracheobronchial Relaxation {#sec3dot2dot2-ijms-20-01667}

Two included studies investigated the tracheobronchial relaxation activity of FTB extract in isolated bronchial and tracheal rings of rats \[[@B17-ijms-20-01667],[@B56-ijms-20-01667]\]. Chan claimed that peimine (A1), peiminine (A2), ebeiedine (A5), and puqietinone (A13) extracted from FTB relaxed the tracheobronch in vitro with 6.9 ± 0.1, 6.4 ± 0.12, 6.3 ± 0.09 and 5.7 ± 0.07 bronchi pD~2~ values respectively and 6.9 ± 0.12, 6.8 ± 0.18, 6.5 ± 0.08 and 6.0 ± 0.16 tracheas pD~2~ values \[[@B17-ijms-20-01667]\]. pD~2~ values, also called pEC~50~, is the negative logarithm of the half maximal effective concentration (EC~50~) and if the pEC~50~ values are larger, the drugs are more effective \[[@B106-ijms-20-01667]\]. Thus, the ranking order of effects within these compounds are peimine (A1) ≥ peiminine (A2) \> ebeiedine (A5) \> puqietinone (A13) \[[@B17-ijms-20-01667]\]. The researcher believed that the mechanisms of action of tracheobronchial relaxation activity of FTB may be related to activation of Ca^2+^-activated K^+^ channels, since peimine (A1), peiminine (A2) and ebeiedine (A5) inhibited Ca^2+^-induced contraction (concentration: 3 mM Ca^2+^) during the study \[[@B17-ijms-20-01667]\]. Another recent study also investigated the pD~2~ values of FTB on tracheobronchial relaxation activity \[[@B56-ijms-20-01667]\]. The results indicated that the total alkaloids of FTB have tracheobronchial relaxation activity with 6.66 ± 0.06 bronchi pD~2~ values and 6.71 ± 0.03 tracheas pD~2~ values, significantly higher than the crude water extract (4.7 ± 0.07 bronchi pD~2~ values and 4.63 ± 0.14 tracheas pD2 values) \[[@B56-ijms-20-01667]\]. These two studies indicated that FTB could have tracheobronchial relaxation activity, due to its alkaloids, such as peimine (A1), peiminine (A2), ebeiedine (A5) and puqietinone (A13) \[[@B17-ijms-20-01667],[@B56-ijms-20-01667]\]. However, more solid evidence is required to identify the best treatment dosage of these compounds, as well as the effects of other alkaloids on tracheobronchial relaxation activity.

### 3.2.3. Antitussive Effect {#sec3dot2dot3-ijms-20-01667}

Two In vivo studies were conducted by the same research team to identify the antitussive effect of FTB in guinea pigs \[[@B89-ijms-20-01667],[@B90-ijms-20-01667]\]. Both of them indicated that the frequency of cough was significantly reduced (15 ± 7.6/5 min) and the remission period was prolonged (73.65 ± 43.02 t/s) to five minutes after oral administration of micro powders of FTB, compared to the purified water control group (24.2 ± 10.75/5 min and 46.99 ± 12.02 t/s respectively) \[[@B89-ijms-20-01667],[@B90-ijms-20-01667]\]. Another study compared the antitussive effects of FTB in mice harvested in four different places in China \[[@B27-ijms-20-01667]\]. The results indicated that a high dose of FTB aqueous extract (0.104 g/kg) harvested in all four different places significantly reduced the frequency of cough (*p* \< 0.01) and increased the remission period (*p* \< 0.05) \[[@B27-ijms-20-01667]\]. As an important antitussive herb in ancient China, micro powders and aqueous extract of FTB appeared to have antitussive activity in experimental studies.

### 3.2.4. Expectorant Effect {#sec3dot2dot4-ijms-20-01667}

Two studies described FTB's expectorant effect \[[@B86-ijms-20-01667],[@B89-ijms-20-01667]\]. Yan and colleagues evaluated the expectorant effects of FTB fine powders via the phenol red expectoration test \[[@B89-ijms-20-01667]\]. The results indicated that FTB fine powders significantly reduced the amount of phlegm secretion (phenol red contraction: 1.048 ± 0.09 mg/L), compared to the blank control group (phenol red contraction: 0.691 ± 0.059 mg/L) (mean difference 0.36, 95% confidence interval 0.29--0.42) \[[@B89-ijms-20-01667]\]. The other study assessed the amount of phlegm secretion using a percentage (per hour secretion before and after administration) \[[@B86-ijms-20-01667]\]. The result showed that FTB dramatically reduced the amount of phlegm secretion (203.6%, larger than the standard 170% which indicates effective treatment), compared to the control group (101.2%) \[[@B86-ijms-20-01667]\]. These two studies showed that the fine powders and alcohol extract of FTB produce the expectorant effect evidenced by decreasing the amount of phlegm secretion \[[@B86-ijms-20-01667],[@B89-ijms-20-01667]\]. However, the active compounds related to this effect are still unknown. Further studies should investigate the active chemical constituents in FTB, as well as possible mechanisms of actions related to the expectorant effect.

### 3.2.5. Anti-inflammation {#sec3dot2dot5-ijms-20-01667}

Anti-inflammation is one of the most essential pharmacological effects of FTB, mentioned in five included studies, three in vitro studies \[[@B33-ijms-20-01667],[@B73-ijms-20-01667],[@B88-ijms-20-01667]\] and two In vivo studies \[[@B87-ijms-20-01667],[@B93-ijms-20-01667]\]. Three chemical compounds isolated from FTB, including peimine (A1), ebeiedine (A5) and suchengbeisine (A8), could reduce the expression and production of MUC5AC mucin (common mucin expressed in the airway surface epithelium) in human pulmonary mucoepidermoid NCI-H292 cells \[[@B33-ijms-20-01667]\]. Peimine (A1) was able to block the Kv1.3 ion channel \[[@B88-ijms-20-01667]\]. The Kv1.3 inhibitor is commonly believed to have the anti-inflammatory ability, blocking the human T lymphocytes-induced immune responses \[[@B88-ijms-20-01667],[@B107-ijms-20-01667],[@B108-ijms-20-01667]\]. Another five chemical compounds, including isoverticine (A7), puqiedine (A15), N-demethylpuqietinone (A19), 2-monopalmitin (I2), and zhebeiresinol (J2) reduced the expression of NF-κB level in the human embryonic kidney cells HEK293 \[[@B73-ijms-20-01667]\]. In vivo studies revealed that the aqueous extract of FTB inhibited the abnormal immune response by relieving the inflammation and over the proliferation of fibroblasts of the prostate, as well as reducing the serum level of NO in the mice model with immunological chronic prostatitis/chronic pelvic pain syndrome \[[@B87-ijms-20-01667]\]. Two animal studies reported that the alcohol extract of FTB relieved the swelling of ear and foot plantar induced by xylene and carrageenin respectively in mice \[[@B93-ijms-20-01667]\]. With its anti-inflammatory activities, FTB could be used for many inflammatory disorders, such as pulmonary or tracheobronchial inflammatory disorders, lump or masses \[[@B87-ijms-20-01667],[@B93-ijms-20-01667]\]. Future studies should focus on mechanisms of actions of the active compounds mentioned in these publications, including peimine (A1), ebeiedine (A5) and suchengbeisine (A8), isoverticine (A7), puqiedine (A15), N-demethylpuqietinone (A19), 2-monopalmitin (I2), and zhebeiresinol (J2) for anti-inflammatory activity.

### 3.2.6. Pain Suppression {#sec3dot2dot6-ijms-20-01667}

FTB was found to be a potential pain reliever in two included studies \[[@B88-ijms-20-01667],[@B92-ijms-20-01667]\]. Peimine (A1) extracted from FTB inhibited the Nav1.7 ion channel, which could be a possible mechanism of action of pain suppression \[[@B88-ijms-20-01667]\]. Nav1.7, commonly found in the peripheral nervous system, is one number of the sodium channel family encoded by the SCN9A gene \[[@B109-ijms-20-01667],[@B110-ijms-20-01667],[@B111-ijms-20-01667]\]. Blocking this channel may lead to inherited gene mutations and subsequently lead to pain sensory loss \[[@B112-ijms-20-01667]\]. The alcohol extract of FTB reduced the frequency of mouse writhing (acetic acid induced pain test) and prolonged the remission period of tail-flick latency (thermal stimulus pain test) in mice \[[@B92-ijms-20-01667]\]. The in vitro and in vivo studies mentioned above presented some evidence relevant to the pain suppressive activity of FTB. However, due to limited evidence, it is difficult to thoroughly explain the mechanisms of this action. Further studies could consider using peimine (A1) as an active compound for pain relief in in vitro and in vivo studies.

### 3.2.7. Antioxidation {#sec3dot2dot7-ijms-20-01667}

Recent studies indicated that many herbs, including FTB have an antioxidative effect \[[@B84-ijms-20-01667],[@B85-ijms-20-01667]\]. The total alkaloids extracted from FTB has strong antioxidative capacity that was reflected in the data of 2,2-diphenyl-1-picrylhydrazyl (DPPH) radical scavenging activity (EC~50~: 5.5 mg/mL), 2,2′-azino-bis (3-ethylbenzothiazoline-6-sulphonic acid) radical scavenging activity (EC~50~: 0.3 mg/mL) and ferric reducing capacity test (118.2 mg ascorbic acid equivalent per 100 g) \[[@B85-ijms-20-01667]\]. The polysaccharide extracted from FTB also has an antioxidative effect \[[@B84-ijms-20-01667]\]. Specifically, the DPPH scavenging ratio of FTB was 21.46%. The reducing capacity and total antioxidative capacity of FTB polysaccharide (1 mg/mL) were evaluated using the absorption spectroscopy method (700 nm) with 0.51 and 0.39 absorbance respectively \[[@B84-ijms-20-01667]\]. Notwithstanding the fact that both of the in vitro studies indicated that not only total alkaloids, but also polysaccharide in FTB have a strong antioxidative capacity, in vivo studies are needed to support in vitro findings in future. In addition, identifying the active compounds related to this pharmacological effect is required.

### 3.2.8. Other Pharmacological Effects {#sec3dot2dot8-ijms-20-01667}

FTB also had other pharmacological effects, including anti-ulcer, anti-muscarinic, anti-thyroid, regulation of blood rheological properties, anti-diarrhea and neuroprotection \[[@B8-ijms-20-01667],[@B75-ijms-20-01667],[@B78-ijms-20-01667],[@B82-ijms-20-01667],[@B92-ijms-20-01667],[@B93-ijms-20-01667],[@B94-ijms-20-01667]\]. The alcohol extract of FTB could directly inhibit water immersion-induced or hydrochloric acid-induced gastric ulcer \[[@B92-ijms-20-01667]\], as well as an acetic acid-induced oral ulcer in rats \[[@B94-ijms-20-01667]\]. Three alkaloids, including peimine (A1), peiminine (A2) and puqietinone (A13), could significantly increase the cAMP level in the HEK293 cells transfected with muscarinic M2 receptor \[[@B75-ijms-20-01667]\]. Anti-thyroid activity was detected, evidenced by reduced the serum levels of T~3~, T~4~, cAMP and cGMP, and increasing hypoxia tolerance in hyperthyroidic mice \[[@B82-ijms-20-01667]\]. FTB was able to decrease whole blood viscosity, inhibit erythrocyte aggregation and increase erythrocyte deformability in rats, which means it could regulate blood rheological properties \[[@B78-ijms-20-01667]\]. In addition, the alcohol extract of FTB significantly decreased the frequency of diarrhea induced by castor oil or Fan xie ye (*Folium Sennae*) \[[@B93-ijms-20-01667]\]. The NO level in lipopolysaccharide-activated BV-2 cells was inhibited by ebeiedinone (A6) (IC~50~: 11.45 μM), suchengbeisine (A8) (IC50: 18.02 μM) and frithunbol B (A24) (IC~50~: 16.35 μM) \[[@B8-ijms-20-01667]\]. Moreover, the compound 3β-hydroxy-5α-jervanin-12-en-6-one (A26) significantly increased the nerve growth factor level (134.81 ± 3.66%) in C6 glioma cells \[[@B8-ijms-20-01667]\]. In vivo and in vitro studies demonstrated that FTB may have a series of pharmacological effects. However, evidence for each pharmacological effect of FTB is limited. More in vitro and in vivo studies are needed to elucidate the possible mechanisms of actions of each effect.

3.3. Pharmacokinetics of FTB {#sec3dot3-ijms-20-01667}
----------------------------

Only six included studies of this review provided information on the pharmacokinetics of FTB's chemical compounds, such as peimine (A1), peiminine (A2) and peimisine (A9) \[[@B45-ijms-20-01667],[@B49-ijms-20-01667],[@B59-ijms-20-01667],[@B76-ijms-20-01667],[@B77-ijms-20-01667],[@B83-ijms-20-01667]\]. The experimental study indicated that peiminine (A2), extracted by 70% or 90% ethyl alcohol, could penetrate excised rat skin using ultraviolet radiation testing method \[[@B83-ijms-20-01667]\]. The penetration rates were similar in both concentrations of solvent. Although the penetration amount of peiminine (A2) in different concentrations of ethyl alcohol was similar and increased over time, the percutaneous permeability coefficient was limited and low in both groups. A sensitive, rapid and maneuverable method, LC-TRAP-MS, was developed to identify whether the nine alkaloids extracted from FTB could be absorbed by rats in plasma after oral administration \[[@B45-ijms-20-01667]\]. The study claimed that six compounds, including peimine (A1), peiminine (A2), ebeiedinone (A6), isoverticine (A7), peimisine (A9), and puqiedinone (A14) were detected in plasma whereas three of them, including ebeiedine (A5), zhebeininoside (A11) and puqiedine (A15) were not. Furthermore, the parameters of pharmacokinetics of peimine (A1), peiminine (A2) and peimisine (A9) were investigated in four studies, including maximum concentration (C~max~), elimination half-life (T~1/2~), time to reach C~max~ (T~max~), oral clearance (CL/F), volume distribution/bioavailability (V/F), area under the concentration-time curve (AUC) from zero to t and from zero to infinite time \[[@B49-ijms-20-01667],[@B59-ijms-20-01667],[@B76-ijms-20-01667],[@B77-ijms-20-01667]\]. [Table 3](#ijms-20-01667-t003){ref-type="table"} summarizes the pharmacokinetic parameters of peimine (A1), peiminine (A2) and peimisine (A9) in these four studies.

One of these four studies compared the differences of pharmacokinetics, tissue distribution and excretion between male and female rats \[[@B77-ijms-20-01667]\]. [Table 3](#ijms-20-01667-t003){ref-type="table"} shows that in this study, the index (Cmax, Tmax, AUC0-t and AUC0-∞) of male rats was significantly higher than the female's while the CL/F and V/F statistics were lower, which indicates that the elimination of peimine and peiminine in male rat plasma was slower than the female's (*p* \< 0.05). In contrast, the results also showed that the cumulative excretion of peimine (A1) and peiminine (A2) in male rat urine were significantly higher than that in female. Additionally, peimine (A1) and peiminine (A2) were found in various tissues of rats, including liver, heart, spleen, kidney, lung, uterus, ovary, brain, testis, muscle and skin \[[@B77-ijms-20-01667]\]. The concentrations of both alkaloids in male tissues were significantly higher than female's, except for muscle and skin. On the other hand, the pharmacokinetic parameters in Tong's study were substantially lower than those in the other three studies, and this may be due to its very low administration dose (0.45 g/kg) \[[@B49-ijms-20-01667]\]. Current pharmacokinetic studies of FTB are mainly focused on the absorption, distribution and excretion of peimine (A1), peiminine (A2) and some other alkaloids in rats. The examination of other chemical compounds will assist in understanding the pharmacokinetic profile of FTB. Further research should consider comprehensively investigating the pharmacokinetics of other chemical components listed in [Table 1](#ijms-20-01667-t001){ref-type="table"}.

3.4. Toxicity of FTB {#sec3dot4-ijms-20-01667}
--------------------

FTB is considered a non-toxic or low toxic herb for the past several thousands of years with a recommended dose of 5−10 g (equivalent to 83--167 mg/kg body weight) for adults \[[@B2-ijms-20-01667]\]. Recently, three included studies were published which are relevant to the toxicity of FTB \[[@B79-ijms-20-01667],[@B81-ijms-20-01667],[@B92-ijms-20-01667]\]. An in vivo study using 110 male Wistar rats indicated that the FTB water extract (10 g/kg, ig, for seven days) did not increase the creatine kinase and lactate dehydrogenase levels compared to the saline group \[[@B79-ijms-20-01667]\]. The histopathological examination in this study showed that the basic structure of heart tissue and cardiac muscle fibers were normal, compared to the saline group. This revealed that the extract of FTB did not induce cardiotoxicity in rats. Nonetheless, irregular cell nuclear arrangement and nonuniform cytoplasm staining were found in the FTB group.

Another two studies investigated the median lethal dose (LD~50~) of oral intake FTB extract on 40 and 60 mice respectively via the acute toxicity test for seven \[[@B92-ijms-20-01667]\] and 14 days \[[@B81-ijms-20-01667]\] respectively. The results showed that the LD~50~ was 12.2 ± 2.2 g/kg \[[@B92-ijms-20-01667]\] and 53 mg/kg \[[@B81-ijms-20-01667]\] on mice respectively. Due to insufficient information, it is difficult to interpret the dramatic difference of the LD~50~ between these two studies. Acute toxic symptoms were observed, such as tremors, restlessness, drowsiness, asthma, convulsions, urinary incontinence, and tail-erecting reaction, and the cause of death could be pulmonary venous pleonaemia and respiratory failure \[[@B81-ijms-20-01667],[@B92-ijms-20-01667]\]. A sub-chronic toxicity test was conducted on 120 rats after oral-intake of 1 or 3 mg/kg FTB extract for 26 weeks \[[@B81-ijms-20-01667]\]. The findings indicated that the safe dose of FTB extract could be 1 mg/kg without any toxicity symptoms whereas tremor and reduction of spontaneous motor activities were found in the 3 mg/kg group. Furthermore, hematology, blood biochemistry, as well as weight and histology of rats' organ were observed without any significant changes within 26 weeks \[[@B81-ijms-20-01667]\].

The recommended dose listed in the Pharmacopeia of the People's Republic of China seems to be safe, as the aqueous extract of FTB in recommended dose could be 0.0415--0.0835 mg/kg (0.05% extraction efficiency), which is approximately 10--25 times lower than 1 mg/kg \[[@B81-ijms-20-01667]\]. Nonetheless, some challenges should not be neglected, such as the tremendous difference of LD~50~ in two different studies and the adverse effects found in the animal studies. Therefore, more experimental and clinical toxicity studies are needed, with a focus on the estimation of LD~50~, as well as the adverse effects of FTB at both low and high doses.

4. Conclusions {#sec4-ijms-20-01667}
==============

It is worth noting that this study was the first to systematically review the traditional uses, phytochemistry, pharmacodynamics, pharmacokinetics and toxicity of FTB. The crude herb FTB contains more than 100 chemical constituents in 11 categories with 13 possible pharmacological activities. Included studies revealed that these pharmacological activities may be mainly attributed to the alkaloids isolated from FTB. Its multiple compounds and effects may contribute to novel drug discovery for the management of multiple conditions. Current studies indicated that additional or even synergistic therapeutic effects could be produced, and may be superior to a single component, when combined multiple active constituents are used, because of the concurrent and selective interactions with multiple target proteins of a disease or a condition, such as malignant tumor, respiratory disorders and inflammation. Classic literature also suggested that there are multiple actions which may be performed by FTB. However, the mechanisms of actions of FTB are still not clear. The relationship between active chemical constituents and possible mechanisms needed to be systematically evaluated as well. High quality and well-designed in vivo and in vitro studies on the mechanisms of actions, pharmacokinetic and toxicity of FTB are recommended. A comprehensive and thorough investigation of the multi-target network pharmacology of FTB could provide insights into various conditions, and thus support evidence-based practice.

Supplementary materials can be found at <https://www.mdpi.com/1422-0067/20/7/1667/s1>.
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###### 

Summary of the 134 chemical constituents isolated from Fritillariae Thunbergii Bulbus.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  No.     Derivatives and Constitutions                                                 Molecular Formula       PubChem CID/SID                                        Molecule Weight (g/mol)   Method                                                                                                                                                                                                                                                                                                                                                                                                          
  ------- ----------------------------------------------------------------------------- ----------------------- ------------------------------------------------------ ------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **A**   **Alkaloids (*n* = 26)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  A1      Peimine                                                                       C~27~H~45~NO~3~         131900                                                 431.661                   HPLC \[[@B33-ijms-20-01667]\]; HPLC-ELSD \[[@B44-ijms-20-01667],[@B60-ijms-20-01667],[@B63-ijms-20-01667]\]; HPLC-ESI/MS \[[@B70-ijms-20-01667]\]; HPLC-MS \[[@B21-ijms-20-01667]\]; UPLC-ELSD \[[@B26-ijms-20-01667]\]; LC/ESI-QTOF-MS/MS \[[@B72-ijms-20-01667]\]; Pre-column derivatization HPLC \[[@B38-ijms-20-01667]\]; GC \[[@B55-ijms-20-01667]\]; ^1^HNMR/^13^CNMR/HR-FAB-MS \[[@B8-ijms-20-01667]\]   HPLC \[[@B18-ijms-20-01667],[@B20-ijms-20-01667]\]; HPLC-ELSD \[[@B17-ijms-20-01667],[@B27-ijms-20-01667],[@B28-ijms-20-01667],[@B29-ijms-20-01667],[@B32-ijms-20-01667],[@B36-ijms-20-01667],[@B47-ijms-20-01667],[@B51-ijms-20-01667]\]; HSCCC-ELSD \[[@B31-ijms-20-01667]\]; UPLC-CAD/HPLC-ELSD \[[@B42-ijms-20-01667]\]; UHPLC-MS/MS \[[@B59-ijms-20-01667]\]; LC-LTQ-Orbitrap MS^n^ \[[@B22-ijms-20-01667]\]; LC-TRAP-MS/LC-ESI-MS \[[@B45-ijms-20-01667]\]; ESI-MS \[[@B73-ijms-20-01667]\]; TLCS \[[@B23-ijms-20-01667],[@B48-ijms-20-01667],[@B57-ijms-20-01667]\]; ^13^CNMR \[[@B69-ijms-20-01667]\]; Determination of colorimetry \[[@B23-ijms-20-01667]\]; RRLC-MS/MS \[[@B49-ijms-20-01667]\]; MS/IR/^1^HNMR/^13^CNMR \[[@B75-ijms-20-01667]\]; GC \[[@B37-ijms-20-01667]\]; GC direct \[[@B17-ijms-20-01667]\]; Indirect UV detection \[[@B41-ijms-20-01667]\]; Paper partition chromatography \[[@B46-ijms-20-01667]\]; Aid-dye ofnrimetry \[[@B24-ijms-20-01667],[@B39-ijms-20-01667]\]

  A2      Peiminine                                                                     C~27~H~43~NO~3~         167691                                                 429.645                   HPLC-MS \[[@B21-ijms-20-01667]\]; HPLC-ELSD \[[@B60-ijms-20-01667]\]; HPLC-ESI/MS \[[@B70-ijms-20-01667]\]; Pre-column derivatization HPLC \[[@B38-ijms-20-01667]\]; UPLC-ELSD \[[@B26-ijms-20-01667]\]; LC/ESI-QTOF-MS/MS \[[@B72-ijms-20-01667]\]; GC \[[@B56-ijms-20-01667]\]; ^1^HNMR/^13^CNMR/HR-FAB-MS \[[@B8-ijms-20-01667]\]; Acid dye two-phase titration \[[@B50-ijms-20-01667]\]                     HPLC \[[@B17-ijms-20-01667],[@B18-ijms-20-01667],[@B20-ijms-20-01667]\]; HPLC-ELSD \[[@B27-ijms-20-01667],[@B28-ijms-20-01667],[@B29-ijms-20-01667],[@B32-ijms-20-01667],[@B36-ijms-20-01667],[@B47-ijms-20-01667]\]; HPLC-CAD/HPLC-ELSD \[[@B42-ijms-20-01667]\]; HSCCC-ELSD \[[@B31-ijms-20-01667]\]; ESI-MS \[[@B73-ijms-20-01667]\]; UHPLC--MS/MS \[[@B59-ijms-20-01667]\]; TLCS \[[@B23-ijms-20-01667],[@B48-ijms-20-01667],[@B57-ijms-20-01667]\]; LC-LTQ-Orbitrap MS^n^ \[[@B22-ijms-20-01667]\]; LC-TRAP-MS/LC-ESI-MS \[[@B45-ijms-20-01667]\]; ^13^CNMR \[[@B69-ijms-20-01667]\]; Determination of colorimetry \[[@B23-ijms-20-01667]\]; RRLC-MS/MS \[[@B49-ijms-20-01667]\]; MS/IR/^1^HNMR/^13^CNMR \[[@B75-ijms-20-01667]\]; GC \[[@B37-ijms-20-01667]\]; GC direct \[[@B17-ijms-20-01667]\]; Indirect UV detection \[[@B41-ijms-20-01667]\]

  A3      Zhebeinine                                                                    C~27~H~45~NO~3~         21121503                                               431.661                   N/A                                                                                                                                                                                                                                                                                                                                                                                                             TLC \[[@B69-ijms-20-01667]\]; ^13^CNMR \[[@B69-ijms-20-01667]\]

  A4      Zhebeinone                                                                    C~27~H~43~NO~3~         NF ([Figure 2](#ijms-20-01667-f002){ref-type="fig"})   429.645                   N/A                                                                                                                                                                                                                                                                                                                                                                                                             GC-MS \[[@B65-ijms-20-01667]\]

  A5      Ebeiedine                                                                     C~27~H~45~NO~2~         101324888                                              415.662                   HPLC \[[@B33-ijms-20-01667]\]; GC \[[@B56-ijms-20-01667]\]; LC/ESI-QTOF-MS/MS \[[@B72-ijms-20-01667]\]; ^1^HNMR/^13^CNMR/HR-FAB-MS \[[@B8-ijms-20-01667]\]                                                                                                                                                                                                                                                      GC \[[@B37-ijms-20-01667]\]; GC direct \[[@B17-ijms-20-01667]\]; LC-TRAP-MS/LC-ESI-MS \[[@B45-ijms-20-01667]\]

  A6      Ebeiedinone                                                                   C~27~H~43~NO~2~         102062796                                              413.646                   GC \[[@B56-ijms-20-01667]\]; ^1^HNMR/^13^CNMR/HR-FAB-MS \[[@B8-ijms-20-01667]\]                                                                                                                                                                                                                                                                                                                                 GC \[[@B37-ijms-20-01667]\]; GC direct \[[@B17-ijms-20-01667]\]; LC-TRAP-MS/LC-ESI-MS \[[@B44-ijms-20-01667]\]; LC-LTQ-Orbitrap MS^n^ \[[@B22-ijms-20-01667]\]; HPLC-ELSD \[[@B17-ijms-20-01667],[@B36-ijms-20-01667]\]

  A7      Isoverticine                                                                  C~27~H~45~NO~3~         21573744                                               431.661                   GC \[[@B56-ijms-20-01667]\]; LC/ESI-QTOF-MS/MS \[[@B72-ijms-20-01667]\]; ^1^HNMR/^13^CNMR/HR-FAB-MS \[[@B8-ijms-20-01667]\]                                                                                                                                                                                                                                                                                     GC \[[@B37-ijms-20-01667]\]; GC direct \[[@B17-ijms-20-01667]\]; LC-TRAP-MS/LC-ESI-MS \[[@B45-ijms-20-01667]\]; HPLC-ELSD \[[@B17-ijms-20-01667],[@B36-ijms-20-01667]\]; ESI-MS \[[@B73-ijms-20-01667]\]; TLCS \[[@B57-ijms-20-01667]\]

  A8      Suchengbeisine                                                                C~27~H~43~NO~3~         102112537                                              429.645                   HPLC \[[@B33-ijms-20-01667]\]; ^1^HNMR/^13^CNMR/HR-FAB-MS \[[@B8-ijms-20-01667]\]                                                                                                                                                                                                                                                                                                                               N/A

  A9      Peimisine                                                                     C~27~H~41~NO~3~         161294                                                 427.629                   LC/ESI-QTOF-MS/MS \[[@B72-ijms-20-01667]\]; UPLC-ELSD \[[@B26-ijms-20-01667]\]                                                                                                                                                                                                                                                                                                                                  LC-TRAP-MS/LC-ESI-MS \[[@B45-ijms-20-01667]\]; HPLC-ELSD \[[@B17-ijms-20-01667],[@B36-ijms-20-01667],[@B47-ijms-20-01667]\]; TLC \[[@B68-ijms-20-01667]\]; TLCS \[[@B57-ijms-20-01667]\]; LC-LTQ-Orbitrap MS^n^ \[[@B22-ijms-20-01667]\]; RRLC-MS/MS \[[@B49-ijms-20-01667]\]

  A10     Peimisine-N-oxide                                                             C~27~H~42~NO~4~         NF                                                     444.636                   N/A                                                                                                                                                                                                                                                                                                                                                                                                             LC-LTQ-Orbitrap MS^n^ \[[@B22-ijms-20-01667]\]

  A11     Zhebeininoside                                                                C~33~H~55~NO~8~         NF ([Figure 2](#ijms-20-01667-f002){ref-type="fig"})   593.802                   LC/ESI-QTOF-MS/MS \[[@B72-ijms-20-01667]\]                                                                                                                                                                                                                                                                                                                                                                      LC-TRAP-MS/LC-ESI-MS \[[@B45-ijms-20-01667]\]; LC-LTQ-Orbitrap MS^n^ \[[@B22-ijms-20-01667]\]; ^13^CNMR/Infrared spectra analysis \[[@B67-ijms-20-01667]\]; ESI-MS \[[@B73-ijms-20-01667]\]

  A12     Verticinone-3-β-[d]{.smallcaps}-glucoside                                     C~33~H~53~NO~8~         90479257                                               591.786                   LC/ESI-QTOF-MS/MS \[[@B72-ijms-20-01667]\]                                                                                                                                                                                                                                                                                                                                                                      N/A

  A13     Puqietinone                                                                   C~28~H~47~NO~2~         10693900                                               429.689                   LC/ESI-QTOF-MS/MS \[[@B72-ijms-20-01667]\]                                                                                                                                                                                                                                                                                                                                                                      N/A

  A14     Puqiedinone                                                                   C~27~H~43~NO~2~         126149                                                 413.646                   LC/ESI-QTOF-MS/MS \[[@B72-ijms-20-01667]\]                                                                                                                                                                                                                                                                                                                                                                      LC-TRAP-MS/LC-ESI-MS \[[@B45-ijms-20-01667]\]; LC-LTQ-Orbitrap MS^n^ \[[@B22-ijms-20-01667]\]

  A15     Puqiedine                                                                     C~27~H~45~NO~2~         101400593                                              415.662                   LC/ESI-QTOF-MS/MS \[[@B72-ijms-20-01667]\]                                                                                                                                                                                                                                                                                                                                                                      LC-TRAP-MS/LC-ESI-MS \[[@B45-ijms-20-01667]\]; ESI-MS \[[@B73-ijms-20-01667]\]

  A16     Eduardine                                                                     C~27~H~43~NO~2~         NF ([Figure 2](#ijms-20-01667-f002){ref-type="fig"})   413.646                   N/A                                                                                                                                                                                                                                                                                                                                                                                                             GC-MS \[[@B66-ijms-20-01667]\]

  A17     Zhebeirine                                                                    C~27~H~43~NO~2~         NF ([Figure 2](#ijms-20-01667-f002){ref-type="fig"})   413.646                   N/A                                                                                                                                                                                                                                                                                                                                                                                                             GC-MS \[[@B66-ijms-20-01667]\]; ESI-MS \[[@B73-ijms-20-01667]\]

  A18     2,3-deoxyladenosine                                                           C~10~H~11~N~5~O~2~      NF                                                     233.231                   N/A                                                                                                                                                                                                                                                                                                                                                                                                             ESI-MS \[[@B73-ijms-20-01667]\]

  A19     N-demethylpuqietinone                                                         C~27~H~45~NO~2~         11304576                                               415.662                   N/A                                                                                                                                                                                                                                                                                                                                                                                                             ESI-MS \[[@B73-ijms-20-01667]\]

  A20     Puqienine B                                                                   C~28~H~45~NO~2~         11419389                                               443.672                   N/A                                                                                                                                                                                                                                                                                                                                                                                                             ESI-MS \[[@B73-ijms-20-01667]\]

  A21     Zhebeinone-3-β-[d]{.smallcaps}-glucoside                                      C~33~H~55~NO~8~         NF ([Figure 2](#ijms-20-01667-f002){ref-type="fig"})   593.802                   N/A                                                                                                                                                                                                                                                                                                                                                                                                             ESI-MS \[[@B73-ijms-20-01667]\]

  A22     Peiminoside                                                                   C~33~H~55~NO~7~         90479565                                               577.803                   N/A                                                                                                                                                                                                                                                                                                                                                                                                             Paper partition chromatography \[[@B46-ijms-20-01667]\]

  A23     Frithunbol A                                                                  C~27~H~41~NO~4~         NF ([Figure 2](#ijms-20-01667-f002){ref-type="fig"})   443.628                   ^1^HNMR/^13^CNMR/HR-FAB-MS \[[@B8-ijms-20-01667]\]                                                                                                                                                                                                                                                                                                                                                              N/A

  A24     Frithunbol B                                                                  C~27~H~42~NO~3~         NF ([Figure 2](#ijms-20-01667-f002){ref-type="fig"})   428.637                   ^1^HNMR/^13^CNMR/HR-FAB-MS \[[@B8-ijms-20-01667]\]                                                                                                                                                                                                                                                                                                                                                              N/A

  A25     Eduardinine                                                                   C~27~H~45~NO~2~         NF ([Figure 2](#ijms-20-01667-f002){ref-type="fig"})   415.662                   ^1^HNMR/^13^CNMR/HR-FAB-MS \[[@B8-ijms-20-01667]\]                                                                                                                                                                                                                                                                                                                                                              N/A

  A26     3β-hydroxy-5α-jervanin-12-en-6-one\                                           C~27~H~42~NO~3~         NF ([Figure 2](#ijms-20-01667-f002){ref-type="fig"})   428.637                   ^1^HNMR/^13^CNMR/HR-FAB-MS \[[@B8-ijms-20-01667]\]                                                                                                                                                                                                                                                                                                                                                              N/A

  **B**   **Compounds from essential oils (*n* = 29)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  B1      δ-elemene                                                                     C~15~H~24~              12309449                                               204.357                   N/A                                                                                                                                                                                                                                                                                                                                                                                                             GC-MS \[[@B16-ijms-20-01667]\]

  B2      δ-selinene                                                                    C~15~H~24~              520383                                                 204.357                   N/A                                                                                                                                                                                                                                                                                                                                                                                                             GC-MS \[[@B16-ijms-20-01667]\]

  B3      Tetradecanoic acid                                                            C~14~H~28~O~2~          11005                                                  228.376                   N/A                                                                                                                                                                                                                                                                                                                                                                                                             GC-MS \[[@B16-ijms-20-01667]\]

  B4      Pentadecanoic acid                                                            C~15~H~30~O~2~          13849                                                  242.403                   N/A                                                                                                                                                                                                                                                                                                                                                                                                             GC-MS \[[@B16-ijms-20-01667]\]

  B5      Hexadecanoic acid, methyl ester                                               C~17~H~34~O~2~          8181                                                   270.457                   N/A                                                                                                                                                                                                                                                                                                                                                                                                             GC-MS \[[@B16-ijms-20-01667],[@B25-ijms-20-01667]\]

  B6      9-hexadecenoic acid                                                           C~16~H~30~O~2~          5282745                                                254.414                   N/A                                                                                                                                                                                                                                                                                                                                                                                                             GC-MS \[[@B16-ijms-20-01667]\]

  B7      N-hexadecanoic acid                                                           C~16~H~32~O~2~          985                                                    256.43                    N/A                                                                                                                                                                                                                                                                                                                                                                                                             GC-MS \[[@B16-ijms-20-01667]\]

  B8      Kaur-15-ene                                                                   C~20~H~32~              521318                                                 272.476                   N/A                                                                                                                                                                                                                                                                                                                                                                                                             GC-MS \[[@B16-ijms-20-01667]\]

  B9      Heptadecanoic acid                                                            C~17~H~34~O~2~          10465                                                  270.457                   N/A                                                                                                                                                                                                                                                                                                                                                                                                             GC-MS \[[@B16-ijms-20-01667]\]

  B10     Kaurene                                                                       C~20~H~32~              91746569                                               272.476                   N/A                                                                                                                                                                                                                                                                                                                                                                                                             GC-MS \[[@B16-ijms-20-01667]\]

  B11     9,12-Octadecadienoic acid (Z,Z)-,\                                            C~19~H~34~O~2~          5284421                                                294.479                   N/A                                                                                                                                                                                                                                                                                                                                                                                                             GC-MS \[[@B16-ijms-20-01667]\]
          methyl ester                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  B12     9-Tetradecenal, (Z)-                                                          C~14~H~26~O             5364471                                                210.361                   N/A                                                                                                                                                                                                                                                                                                                                                                                                             GC-MS \[[@B16-ijms-20-01667]\]

  B13     9,12-Octadecadienoic acid, methyl ester, (E, E)-\                             C~19~H~34~O~2~          135058711                                              294.479                   N/A                                                                                                                                                                                                                                                                                                                                                                                                             GC-MS \[[@B16-ijms-20-01667]\]

  B14     Oleic acid                                                                    C~18~H~34~O~2~          445639                                                 282.468                   N/A                                                                                                                                                                                                                                                                                                                                                                                                             GC-MS \[[@B16-ijms-20-01667]\]

  B15     Linoleic acid, ethyl ester                                                    C~2036~O~2~             5282184                                                308.506                   N/A                                                                                                                                                                                                                                                                                                                                                                                                             GC-MS \[[@B16-ijms-20-01667]\]

  B16     Butylated hydroxytoluene                                                      C~15~H~24~O             31404                                                  220.356                   N/A                                                                                                                                                                                                                                                                                                                                                                                                             GC-MS (Du et al., 2018)

  B17     L-(+)-Ascorbic acid 2,6-\                                                     C~38~H~68~O~8~          54722209                                               652.954                   N/A                                                                                                                                                                                                                                                                                                                                                                                                             GC-MS (Du et al., 2018)
          dihexadecanoate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  B18     Ethyl 9-hexadecenoate                                                         C~18~H~34~O~2~          5364759                                                282.468                   N/A                                                                                                                                                                                                                                                                                                                                                                                                             GC-MS \[[@B25-ijms-20-01667]\]

  B19     Hexadecanoic acid, ethyl ester                                                C~18~H~36~O~2~          12366                                                  284.484                   N/A                                                                                                                                                                                                                                                                                                                                                                                                             GC-MS \[[@B25-ijms-20-01667]\]

  B20     1H-Naphtho \[2,1-B\] pyran, 3-ethenyldodecahydro-3,4a,7,7,10a-pentamethyl-\   C~20~H~34~O             273540178                                              290.491                   N/A                                                                                                                                                                                                                                                                                                                                                                                                             GC-MS \[[@B25-ijms-20-01667]\]

  B21     Kaur-16-ene                                                                   C~20~H~32~O             520687                                                 272.476                   N/A                                                                                                                                                                                                                                                                                                                                                                                                             GC-MS \[[@B25-ijms-20-01667]\]

  B22     9,11-Octadecadienoic acid, methyl ester, (E, E)-\                             C~19~H~34~O~2~          319301067                                              294.479                   N/A                                                                                                                                                                                                                                                                                                                                                                                                             GC-MS \[[@B25-ijms-20-01667]\]

  B23     9,12-Octadecadienoic acid                                                     C~18~H~32~O~2~          5282457                                                280.452                   N/A                                                                                                                                                                                                                                                                                                                                                                                                             GC-MS \[[@B25-ijms-20-01667]\]

  B24     Linoleic acid, ethyl ester                                                    C~20~H~36~O~2~          5282184                                                308.506                   N/A                                                                                                                                                                                                                                                                                                                                                                                                             GC-MS \[[@B25-ijms-20-01667]\]

  B25     Octadecanoic acid, ethyl ester                                                C~20~H~40~O~2~          8122                                                   312.538                   N/A                                                                                                                                                                                                                                                                                                                                                                                                             GC-MS \[[@B25-ijms-20-01667]\]

  B26     2(1H)-Phenanthrenone, 3,4,4a,4b,5,6,7,8,10,10a-decahydro-\                    C~19~H~30~O             621255                                                 274.448                   N/A                                                                                                                                                                                                                                                                                                                                                                                                             GC-MS \[[@B25-ijms-20-01667]\]
          1,1,4a,7,7-pentamethyl, \[4aR-(4a.α., 4b.β.,10a.β.)\]-                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  B27     3-Methyleneandrostan-17-ol                                                    C~20~H~32~O             625647                                                 288.475                   N/A                                                                                                                                                                                                                                                                                                                                                                                                             GC-MS \[[@B25-ijms-20-01667]\]

  B28     Androst-4-en-3-one, 17-hydroxy-, (17.β.)\                                     C~19~H~28~O~2~          50049744                                               288.431                   N/A                                                                                                                                                                                                                                                                                                                                                                                                             GC-MS \[[@B25-ijms-20-01667]\]

  B29     Podocarp-7-en-3.β.-ol, 13.β.-methyl-13-vinyl-\                                C~20~H~32~O             620519                                                 288.475                   N/A                                                                                                                                                                                                                                                                                                                                                                                                             GC-MS \[[@B25-ijms-20-01667]\]

  **C**   **Diterpenoids (*n* = 13)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  C1      Isopimaran-19-ol                                                              C~20~H~32~O             75399514                                               288.475                   N/A                                                                                                                                                                                                                                                                                                                                                                                                             ^1^HNMR/^13^CNMR \[[@B35-ijms-20-01667]\]

  C2      Isopimaran-19-oic acid, methyl ester                                          C~21~H~32~O~2~          NF ([Figure 2](#ijms-20-01667-f002){ref-type="fig"})   316.485                   N/A                                                                                                                                                                                                                                                                                                                                                                                                             ^1^HNMR/^13^CNMR \[[@B34-ijms-20-01667],[@B35-ijms-20-01667]\]

  C3      Ent-kauran-16β, 17-diol                                                       C~20~H~34~O~2~          NF ([Figure 2](#ijms-20-01667-f002){ref-type="fig"})   306.49                    N/A                                                                                                                                                                                                                                                                                                                                                                                                             TLC \[[@B68-ijms-20-01667]\]; ^1^HNMR/^13^CNMR \[[@B34-ijms-20-01667],[@B35-ijms-20-01667]\]

  C4      Ent-kauran-16α, 17-diol                                                       C~20~H~34~O~2~          NF ([Figure 2](#ijms-20-01667-f002){ref-type="fig"})   306.49                    N/A                                                                                                                                                                                                                                                                                                                                                                                                             ^1^HNMR/^13^CNMR \[[@B34-ijms-20-01667],[@B35-ijms-20-01667]\]

  C5      Ent-16β, 17-epoxy-kaurane                                                     C~20~H~32~O             79592848                                               288.475                   N/A                                                                                                                                                                                                                                                                                                                                                                                                             ^1^HNMR/^13^CNMR \[[@B35-ijms-20-01667]\]

  C6      Ent-16α-methoxy-kauran-17-ol                                                  C~21~H~36~O~2~          51842049                                               320.517                   N/A                                                                                                                                                                                                                                                                                                                                                                                                             ^1^HNMR/^13^CNMR \[[@B35-ijms-20-01667]\]

  C7      Ent-kaur-15-en-17-ol                                                          C~20~H~32~O             3082069                                                288.475                   N/A                                                                                                                                                                                                                                                                                                                                                                                                             ^1^HNMR/^13^CNMR \[[@B35-ijms-20-01667]\]

  C8      Trans-communol                                                                C~20~H~32~O             51909318                                               288.475                   N/A                                                                                                                                                                                                                                                                                                                                                                                                             ^1^HNMR/^13^CNMR \[[@B34-ijms-20-01667]\]

  C9      Trans-comminic acid, methyl ester                                             C~21~H~32~O~2~          NF ([Figure 2](#ijms-20-01667-f002){ref-type="fig"})   316.485                   N/A                                                                                                                                                                                                                                                                                                                                                                                                             ^1^HNMR/^13^CNMR \[[@B34-ijms-20-01667]\]

  C10     Ent-17-norkauran-16-one                                                       C~19~H~30~O             12740861                                               274.448                   N/A                                                                                                                                                                                                                                                                                                                                                                                                             ^1^HNMR/^13^CNMR \[[@B34-ijms-20-01667]\]

  C11     Ent-15β,16-epoxy-kauran-17-ol                                                 C~20~H~32~O~2~          51511087                                               304.474                   N/A                                                                                                                                                                                                                                                                                                                                                                                                             ^1^HNMR/^13^CNMR \[[@B34-ijms-20-01667]\]

  C12     Ent-16β-hydroxy-kauran-17-yl ent-kaur-15-en-17-oate                           C~40~H~63~O~3~          NF ([Figure 2](#ijms-20-01667-f002){ref-type="fig"})   591.941                   N/A                                                                                                                                                                                                                                                                                                                                                                                                             ^1^HNMR/^13^CNMR \[[@B34-ijms-20-01667]\]

  C13     Ent-(16S)-atisan-13, 17-oxide                                                 C~20~H~32~O             50418337                                               288.475                   N/A                                                                                                                                                                                                                                                                                                                                                                                                             ^1^HNMR/^13^CNMR \[[@B34-ijms-20-01667]\]

  **D**   **Carbohydrates (*n* = 2)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  D1      β-[d]{.smallcaps}-glucose4-1β-[d]{.smallcaps}-galactose                       C~12~H~22~O~11~         NF                                                     342.297                   N/A                                                                                                                                                                                                                                                                                                                                                                                                             HPLC-ELSD \[[@B19-ijms-20-01667]\]

  D2      Sucrose                                                                       C~12~H~22~O~11~         5988                                                   342.297                   N/A                                                                                                                                                                                                                                                                                                                                                                                                             HPLC-ELSD \[[@B19-ijms-20-01667]\]

  **E**   **Sterols (*n* = 2)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  E1      β-sitosterol                                                                  C~29~H~50~O             222284                                                 414.718                   N/A                                                                                                                                                                                                                                                                                                                                                                                                             TLC \[[@B68-ijms-20-01667]\]

  E2      Daucosterol                                                                   C~35~H~60~O~6~          5742590                                                576.859                   N/A                                                                                                                                                                                                                                                                                                                                                                                                             TLC \[[@B68-ijms-20-01667]\]

  **F**   **Amino acids (*n* = 18)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  F1      Glycine                                                                       C~2~H~5~NO~2~           750                                                    75.067                    N/A                                                                                                                                                                                                                                                                                                                                                                                                             HPLC \[[@B64-ijms-20-01667]\]

  F2      Leucine                                                                       C~6~H~13~NO~2~          6106                                                   131.175                   N/A                                                                                                                                                                                                                                                                                                                                                                                                             HPLC \[[@B64-ijms-20-01667]\]

  F3      Methionine                                                                    C~5~H~11~NO~2~S         6137                                                   149.208                   N/A                                                                                                                                                                                                                                                                                                                                                                                                             HPLC \[[@B64-ijms-20-01667]\]

  F4      Tyrosine                                                                      C~9~H~11~NO~3~          6057                                                   181.191                   N/A                                                                                                                                                                                                                                                                                                                                                                                                             HPLC \[[@B64-ijms-20-01667]\]

  F5      Histidine                                                                     C~6~H~9~N~3~O~2~        6274                                                   155.157                   N/A                                                                                                                                                                                                                                                                                                                                                                                                             HPLC \[[@B64-ijms-20-01667]\]

  F6      Threonine                                                                     C~4~H~9~NO~3~           6288                                                   119.12                    N/A                                                                                                                                                                                                                                                                                                                                                                                                             HPLC \[[@B64-ijms-20-01667]\]

  F7      Alanine                                                                       C~3~H~7~NO~2~           5950                                                   89.094                    N/A                                                                                                                                                                                                                                                                                                                                                                                                             HPLC \[[@B64-ijms-20-01667]\]

  F8      Isoleucine                                                                    C~6~H~13~NO~2~          6306                                                   131.175                   N/A                                                                                                                                                                                                                                                                                                                                                                                                             HPLC \[[@B64-ijms-20-01667]\]

  F9      Tryptophan                                                                    C~11~H~12~N~2~O~2~      6305                                                   204.229                   N/A                                                                                                                                                                                                                                                                                                                                                                                                             HPLC \[[@B64-ijms-20-01667]\]

  F10     Cystine                                                                       C~6~H~12~N~2~O~4~S~2~   67678                                                  240.292                   N/A                                                                                                                                                                                                                                                                                                                                                                                                             HPLC \[[@B64-ijms-20-01667]\]

  F11     Lysine                                                                        C~6~H~14~N~2~O~2~       5962                                                   146.19                    N/A                                                                                                                                                                                                                                                                                                                                                                                                             HPLC \[[@B64-ijms-20-01667]\]

  F12     Aspartic acid                                                                 C~4~H~7~NO~4~           5960                                                   133.103                   N/A                                                                                                                                                                                                                                                                                                                                                                                                             HPLC \[[@B64-ijms-20-01667]\]

  F13     Valine                                                                        C~5~H~11~NO~2~          6287                                                   117.148                   N/A                                                                                                                                                                                                                                                                                                                                                                                                             HPLC \[[@B64-ijms-20-01667]\]

  F14     Phenylalanine                                                                 C~8~H~8~O~2~            6140                                                   165.192                   N/A                                                                                                                                                                                                                                                                                                                                                                                                             HPLC \[[@B64-ijms-20-01667]\]

  F15     Proline                                                                       C~5~H~9~NO~2~           145742                                                 115.132                   N/A                                                                                                                                                                                                                                                                                                                                                                                                             HPLC \[[@B64-ijms-20-01667]\]

  F16     Serine                                                                        C~3~H~7~NO~3~           5951                                                   105.093                   N/A                                                                                                                                                                                                                                                                                                                                                                                                             HPLC \[[@B64-ijms-20-01667]\]

  F17     Glutamic acid                                                                 C~5~H~9~NO~4~           33032                                                  147.13                    N/A                                                                                                                                                                                                                                                                                                                                                                                                             HPLC \[[@B64-ijms-20-01667]\]

  F18     Arginine                                                                      C~6~H~14~N~4~O~2~       6322                                                   174.204                   N/A                                                                                                                                                                                                                                                                                                                                                                                                             HPLC \[[@B64-ijms-20-01667]\]

  **G**   **Nucleosides (*n* = 6)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  G1      Uridine                                                                       C~9~H~12~N~2~O~6~       6029                                                   244.203                   LC-ESI-MS^n^ \[[@B70-ijms-20-01667]\]; HPLC-UV-ESI/MS \[[@B70-ijms-20-01667]\]; HPLC \[[@B71-ijms-20-01667]\]                                                                                                                                                                                                                                                                                                   HPLC \[[@B64-ijms-20-01667]\]

  G2      Guanosine                                                                     C~10~H~13~N~5~O~5~      6802                                                   283.244                   LC-ESI-MS^n^ (Zhang, 2008); HPLC-UV-ESI/MS \[[@B70-ijms-20-01667]\]; HPLC \[[@B71-ijms-20-01667]\]                                                                                                                                                                                                                                                                                                              HPLC \[[@B64-ijms-20-01667]\]

  G3      Adenosine                                                                     C~10~H~13~N~5~O~4~      60961                                                  267.245                   LC-ESI-MS^n^ (Zhang, 2008); HPLC-UV-ESI/MS \[[@B70-ijms-20-01667]\]; HPLC \[[@B71-ijms-20-01667]\]                                                                                                                                                                                                                                                                                                              HPLC \[[@B64-ijms-20-01667]\]

  G4      Thymidine                                                                     C~10~H~14~N~2~O~5~      5789                                                   242.231                   LC-ESI-MS^n^ \[[@B70-ijms-20-01667]\]; HPLC-UV-ESI/MS \[[@B70-ijms-20-01667]\]                                                                                                                                                                                                                                                                                                                                  HPLC \[[@B64-ijms-20-01667]\]

  G5      Cytidine                                                                      C~9~H~13~N~3~O~5~       6175                                                   243.219                   N/A                                                                                                                                                                                                                                                                                                                                                                                                             HPLC \[[@B64-ijms-20-01667]\]

  G6      Inosine                                                                       C~10~H~12~N~4~O~5~      6021                                                   268.229                   N/A                                                                                                                                                                                                                                                                                                                                                                                                             HPLC \[[@B64-ijms-20-01667]\]

  **H**   **Nucleobases (*n* = 4)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  H1      Adenine                                                                       C~5~H~5~N~5~            190                                                    135.13                    LC-ESI-MS^n^ (Zhang, 2008); HPLC-UV-ESI/MS (Zhang, 2008)                                                                                                                                                                                                                                                                                                                                                        HPLC \[[@B64-ijms-20-01667]\]

  H2      Hypoxanthine                                                                  C~5~H~4~N~4~O           790                                                    136.114                   N/A                                                                                                                                                                                                                                                                                                                                                                                                             HPLC \[[@B64-ijms-20-01667]\]

  H3      Uracil                                                                        C~4~H~4~N~2~O~2~        1174                                                   112.088                   N/A                                                                                                                                                                                                                                                                                                                                                                                                             HPLC \[[@B64-ijms-20-01667]\]

  H4      Thymine                                                                       C~5~H~6~N~2~O~2~        1135                                                   126.115                   N/A                                                                                                                                                                                                                                                                                                                                                                                                             HPLC \[[@B64-ijms-20-01667]\]

  **I**   **Fatty acids (*n* = 4)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  I1      Vernolic acid                                                                 C~18~H~32~O~3~          6449780                                                296.451                   N/A                                                                                                                                                                                                                                                                                                                                                                                                             ESI-MS \[[@B73-ijms-20-01667]\]

  I2      2-monopalmitin                                                                C~19~H~38~O~4~          123409                                                 330.509                   N/A                                                                                                                                                                                                                                                                                                                                                                                                             ESI-MS \[[@B73-ijms-20-01667]\]

  I3      13(R)-hydroxy-octadeca-(9Z,11E\                                               C~18~H~30~O~3~          643726                                                 294.435                   N/A                                                                                                                                                                                                                                                                                                                                                                                                             ESI-MS \[[@B73-ijms-20-01667]\]
          ,15Z)-trien-oic acid                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  I4      Picropodophyllotoxin                                                          C~22~H~22~O~8~          72435                                                  414.41                    N/A                                                                                                                                                                                                                                                                                                                                                                                                             ^13^CNMR/Infrared spectra analysis \[[@B67-ijms-20-01667]\]

  **J**   **Lignans (*n* = 3)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  J1      Octahydrocurcumin                                                             C~21~H~28~O~6~          11068834                                               376.449                   N/A                                                                                                                                                                                                                                                                                                                                                                                                             ESI-MS \[[@B73-ijms-20-01667]\]

  J2      Zhebeiresinol                                                                 C~14~H~16~O~6~          192547                                                 280.276                   N/A                                                                                                                                                                                                                                                                                                                                                                                                             ESI-MS \[[@B73-ijms-20-01667]\]; ^1^HNMR/^13^CNMR \[[@B30-ijms-20-01667]\]

  J3      Sauriol B                                                                     C~21~H~28~O~6~          15965508                                               376.449                   N/A                                                                                                                                                                                                                                                                                                                                                                                                             ESI-MS \[[@B73-ijms-20-01667]\]

  **K**   **Elements (*n* = 27)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  K1      Aluminum                                                                      Al                      5359268                                                26.982                    ICP-OES \[[@B62-ijms-20-01667]\]                                                                                                                                                                                                                                                                                                                                                                                FAAS \[[@B61-ijms-20-01667]\]; GFAAS \[[@B61-ijms-20-01667]\]

  K2      Arsenic                                                                       As                      5359596                                                74.922                    ICP-AES \[[@B43-ijms-20-01667]\]; ICP-OES \[[@B14-ijms-20-01667]\]                                                                                                                                                                                                                                                                                                                                              ICP-AES \[[@B74-ijms-20-01667]\]; ICP-OES \[[@B15-ijms-20-01667]\]; ICAP \[[@B55-ijms-20-01667]\]; FAAS \[[@B61-ijms-20-01667]\]; GFAAS \[[@B61-ijms-20-01667]\]

  K3      Boron                                                                         B                       5462311                                                10.81                     ICP-OES \[[@B14-ijms-20-01667],[@B62-ijms-20-01667]\]                                                                                                                                                                                                                                                                                                                                                           N/A

  K4      Barium                                                                        Ba                      5355457                                                137.327                   ICP-AES \[[@B58-ijms-20-01667]\]; ICP-OES \[[@B14-ijms-20-01667]\]                                                                                                                                                                                                                                                                                                                                              N/A

  K5      Bismuth                                                                       Bi                      5359367                                                208.98                    ICP-OES \[[@B14-ijms-20-01667]\]                                                                                                                                                                                                                                                                                                                                                                                N/A

  K6      Calcium                                                                       Ca                      5460341                                                40.078                    ICP-OES \[[@B62-ijms-20-01667]\]                                                                                                                                                                                                                                                                                                                                                                                FAAS \[[@B52-ijms-20-01667],[@B53-ijms-20-01667],[@B61-ijms-20-01667]\]; GFAAS \[[@B61-ijms-20-01667]\]

  K7      Cadmium                                                                       Cd                      23973                                                  112.414                   ICP-AES \[[@B43-ijms-20-01667]\]; ICP-OES \[[@B14-ijms-20-01667],[@B62-ijms-20-01667]\]                                                                                                                                                                                                                                                                                                                         ICP-AES \[[@B74-ijms-20-01667]\]; ICP-OES \[[@B15-ijms-20-01667]\]; ICAP \[[@B55-ijms-20-01667]\]; FAAS \[[@B61-ijms-20-01667]\]; GFAAS \[[@B61-ijms-20-01667]\]; AAS \[[@B40-ijms-20-01667]\]

  K8      Cobalt                                                                        Co                      104730                                                 58.933                    ICP-AES \[[@B58-ijms-20-01667]\]; ICP-OES \[[@B14-ijms-20-01667]\]                                                                                                                                                                                                                                                                                                                                              FAAS \[[@B61-ijms-20-01667]\]; GFAAS \[[@B61-ijms-20-01667]\]

  K9      Chromium                                                                      Cr                      23976                                                  51.996                    ICP-AES \[[@B58-ijms-20-01667]\]                                                                                                                                                                                                                                                                                                                                                                                FAAS \[[@B61-ijms-20-01667]\]; GFAAS \[[@B61-ijms-20-01667]\]; AAS \[[@B40-ijms-20-01667]\]

  K10     Copper                                                                        Cu                      23978                                                  63.546                    ICP-AES \[[@B43-ijms-20-01667],[@B58-ijms-20-01667]\]; ICP-OES \[[@B14-ijms-20-01667]\]                                                                                                                                                                                                                                                                                                                         ICP-AES \[[@B74-ijms-20-01667]\]; ICP-OES \[[@B15-ijms-20-01667]\]; ICAP \[[@B55-ijms-20-01667]\]; FAAS \[[@B52-ijms-20-01667],[@B53-ijms-20-01667],[@B61-ijms-20-01667]\]; GFAAS \[[@B61-ijms-20-01667]\]; AAS \[[@B40-ijms-20-01667]\]

  K11     Iron                                                                          Fe                      23925                                                  55.845                    ICP-AES \[[@B43-ijms-20-01667],[@B58-ijms-20-01667]\]; ICP-OES \[[@B14-ijms-20-01667]\]                                                                                                                                                                                                                                                                                                                         ICP-AES \[[@B74-ijms-20-01667]\]; FAAS \[[@B52-ijms-20-01667],[@B53-ijms-20-01667],[@B61-ijms-20-01667]\]; GFAAS \[[@B61-ijms-20-01667]\]; AAS \[[@B40-ijms-20-01667]\]

  K12     Mercury                                                                       Hg                      23931                                                  200.592                   ICP-AES \[[@B43-ijms-20-01667]\]; ICP-OES \[[@B14-ijms-20-01667]\]                                                                                                                                                                                                                                                                                                                                              ICP-OES \[[@B15-ijms-20-01667]\]

  K13     Indium                                                                        In                      5359967                                                114.818                   ICP-OES \[[@B14-ijms-20-01667]\]                                                                                                                                                                                                                                                                                                                                                                                N/A

  K14     Potassium                                                                     K                       5462222                                                39.098                    ICP-OES \[[@B62-ijms-20-01667]\]                                                                                                                                                                                                                                                                                                                                                                                FAAS \[[@B53-ijms-20-01667],[@B61-ijms-20-01667]\]; GFAAS \[[@B61-ijms-20-01667]\]

  K15     Lithium                                                                       Li                      3028194                                                6.94                      ICP-AES \[[@B43-ijms-20-01667]\]                                                                                                                                                                                                                                                                                                                                                                                N/A

  K16     Magnesium                                                                     Mg                      5462224                                                24.305                    ICP-AES \[[@B43-ijms-20-01667]\]; ICP-OES \[[@B62-ijms-20-01667]\]                                                                                                                                                                                                                                                                                                                                              FAAS \[[@B53-ijms-20-01667],[@B61-ijms-20-01667]\]; GFAAS \[[@B61-ijms-20-01667]\]; AAS \[[@B40-ijms-20-01667]\]

  K17     Manganese                                                                     Mn                      23930                                                  54.938                    ICP-AES \[[@B43-ijms-20-01667],[@B58-ijms-20-01667]\]; ICP-OES \[[@B14-ijms-20-01667]\]                                                                                                                                                                                                                                                                                                                         ICP-AES \[[@B74-ijms-20-01667]\]; FAAS \[[@B53-ijms-20-01667],[@B61-ijms-20-01667]\]; GFAAS \[[@B61-ijms-20-01667]\]; ICAP \[[@B55-ijms-20-01667]\]

  K18     Molybdenum                                                                    Mo                      23932                                                  95.95                     ICP-OES \[[@B62-ijms-20-01667]\]                                                                                                                                                                                                                                                                                                                                                                                N/A

  K19     Sodium                                                                        Na                      5360545                                                22.99                     ICP-OES \[[@B62-ijms-20-01667]\]                                                                                                                                                                                                                                                                                                                                                                                FAAS \[[@B53-ijms-20-01667],[@B61-ijms-20-01667]\]; GFAAS \[[@B61-ijms-20-01667]\]

  K20     Nickel                                                                        Ni                      935                                                    58.693                    ICP-AES \[[@B58-ijms-20-01667]\]; ICP-OES \[[@B14-ijms-20-01667],[@B62-ijms-20-01667]\]                                                                                                                                                                                                                                                                                                                         ICAP \[[@B55-ijms-20-01667]\]

  K21     Phosphorus                                                                    P                       5462309                                                30.974                    ICP-OES \[[@B62-ijms-20-01667]\]                                                                                                                                                                                                                                                                                                                                                                                N/A

  K22     Lead                                                                          Pb                      5352425                                                207.2                     ICP-AES \[[@B43-ijms-20-01667]\]; ICP-OES \[[@B14-ijms-20-01667]\]                                                                                                                                                                                                                                                                                                                                              ICP-OES \[[@B15-ijms-20-01667]\]; AAS \[[@B40-ijms-20-01667]\]; ICAP \[[@B55-ijms-20-01667]\]

  K23     Sulfur                                                                        S                       5362487                                                32.06                     ICP-AES \[[@B43-ijms-20-01667]\]                                                                                                                                                                                                                                                                                                                                                                                N/A

  K24     Selenium                                                                      Se                      6326970                                                78.971                    N/A                                                                                                                                                                                                                                                                                                                                                                                                             Spectrophotometry \[[@B54-ijms-20-01667]\]

  K25     Strontium                                                                     Sr                      5359327                                                87.62                     ICP-AES \[[@B43-ijms-20-01667],[@B58-ijms-20-01667]\]; ICP-OES                                                                                                                                                                                                                                                                                                                                                  FAAS \[[@B61-ijms-20-01667]\]; GFAAS \[[@B61-ijms-20-01667]\]

  K26     Vanadium                                                                      V                       23990                                                  50.941                    ICP-AES \[[@B58-ijms-20-01667]\]                                                                                                                                                                                                                                                                                                                                                                                N/A

  K27     Zinc                                                                          Zn                      23994                                                  65.379                    ICP-AES \[[@B43-ijms-20-01667],[@B58-ijms-20-01667]\]; ICP-OES \[[@B14-ijms-20-01667]\]                                                                                                                                                                                                                                                                                                                         ICP-AES \[[@B74-ijms-20-01667]\]; ICP-OES; ICAP \[[@B55-ijms-20-01667]\]; FAAS \[[@B52-ijms-20-01667],[@B53-ijms-20-01667],[@B61-ijms-20-01667]\]; GFAAS \[[@B61-ijms-20-01667]\]; AAS \[[@B40-ijms-20-01667]\]
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Note: N/A: Not applicable; NF: Not found; SRV: Studies reporting a voucher number; SNRV: Studies not reporting voucher number; Corresponding molecular structures refer to PubChem and [Figure 2](#ijms-20-01667-f002){ref-type="fig"}.
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###### 

Characteristics of the 23 included studies relevant to the mechanisms of actions of Fritillariae Thunbergii Bulbus.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Pharmacological Effects/\                     Study Type   Extract                                                                         Characteristics of the Sample                                                   Interventions                                                                                                                                                                                                            Duration                                         Primary Results
  Included Studies                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  --------------------------------------------- ------------ ------------------------------------------------------------------------------- ------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **1. Anti-cancer**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Li et al., 2013 \[[@B80-ijms-20-01667]\]      In vitro     Total alkaloids                                                                 Human lung adenocarcinoma parental cells A549; Resistant cells A549/DDP         Cytotoxicity: FTB 12.5, 25, 50, 100, 200 mg/L and vehicle 0.5% CMC-Na.\                                                                                                                                                  72 h                                             IC~50~ of TAF to A549: 141 ± 5 mg/L;\
                                                                                                                                                                                                                             Multidrug resistance reversal effect: FTB 9 mg/L, cyclosporine A 1 mg/L or tetrandrine 1 mg/L plus DDP (final concentration: 0.01, 0.1, 1, 10, 100 mg/L).\                                                                                                                IC~50~ of TAF to A549/DDP: 298 ± 22 mg/L;\
                                                                                                                                                                                                                             MDR1 mRNA and P-gp expression: A549/DDP + vehicle; A549/DDP + FTB 9 mg/L; A549/DDP + DDP 14 mg/L; A549/DDP + DDP 14 mg/L + FTB 9 mg/L; A549 + vehicle                                                                                                                     FTB was superior to closporine A and tetrandrines in increasing the reversal fold;\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       FTB alone was superior to vehicle in decreasing the MDR1 mRNA and P-gp expression.

                                                In vivo      Total alkaloids                                                                 60 BALB/c nude mice (A549/DDP model)                                            Vehicle 0.5% CMC-Na; DDP 5 mg/kg, ig, qd; TAF 2 mg/kg, ig, qd; DDP 5 mg/kg + FTB 0.5 mg/kg, ig, qd; DDP 5 mg/kg + FTB 1 mg/kg, ig, qd; DDP 5 mg/kg + FTB 2 mg/kg, ig, qd                                                 13 days                                          DDP + TAF was superior to DDP alone in increasing the tumor inhibitory rate.

  Liu et al., 2015 \[[@B9-ijms-20-01667]\]      In vitro     Total alkaloids; Total nucleosides                                              Human hepatocellular carcinoma cell line HepG2, Resistant cell line HepG2/MDR   Blank control; P-gp positive inhibitor verapamil; Total alkaloid, nucleoside, or polysaccharide 5 μg/mL respectively; Total alkaloid, nucleoside, or polysaccharide 50 μg/mL respectively                                1 h                                              Total alkaloids or Total nucleosides in FTB was superior to the control in increasing the restriction of efflux activity of P-gp.

  Yang et al., 2005 \[[@B91-ijms-20-01667]\]    In vitro     Aqueous extract                                                                 Human lung adenocarcinoma parental cells LM~2~                                  Blank control; FZ + FTB (75 + 75, 25 + 25, 5 + 5, 1 + 1 mg/mL respectively); FZ (75, 25, 5 mg/mL respectively); FTB (75, 25, 5 mg/mL respectively)                                                                       48 h                                             FTB alone was superior to control and FZ + FTB in increasing the apoptosis rate.

                                                In vivo      Aqueous extract                                                                 142 SPF C~57~ mice (Human lung adenocarcinoma parental cells LM~2~ model)       Blank control; FZ + FTB (0.8 + 1.6 g/kg, 0.64 + 1.28 g/kg, 0.51 + 1.02 g/kg respectively, ig, qd); FZ (0.8 g/kg, 0.64 g/kg, 0.51 g/kg respectively, ig, qd); FTB (1.6 g/kg, 1.28 g/kg, 1.02 g/kg respectively, ig, qd)   18 days                                          FTB alone was superior to control and FZ + FTB in increasing the tumor inhibitory rate and reducing the number of metastases.

  Tong, 2016 \[[@B49-ijms-20-01667]\]           In vitro     Peimine; Peiminine                                                              Human breast carcinoma cells MCF-7; Resistant cell line MCF-7/ADM               Peimine 12.5--400 μg/mL; Peiminine 12.5--400 μg/mL; ADM (0.78125--100 μg/mL) + Peimine or Peiminine; Paclitaxel (2.5--80 μg/mL) + Peimine or Peiminine                                                                   48 h                                             Both peimine and peiminine could reverse the multi-drug resistant tumor resistance of ADM or paclitaxel

  **2. Tracheobronchial relaxation**                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Chan, 2000 \[[@B17-ijms-20-01667]\]           In vitro     Peimine; Peiminine; Ebeiedine                                                   Rat tracheal and bronchial rings                                                Peimine, Peiminine, Ebeiedine, Imperialine, puqietinone, Salbutamol, Diphenhydramine, Codeine cumulative concentrations 1 nM-100 μM respectively                                                                         Immediate                                        Peimine, peiminine, ebeiedine and puqietinone in FTB could relax the tracheobronch of rats.

  Wu et al., 2018 \[[@B56-ijms-20-01667]\]      In vitro     Total alkaloids                                                                 Rat tracheal and bronchial rings                                                Total alkaloids cumulative concentrations 0-3 g/mL                                                                                                                                                                       Immediate                                        Total alkaloids in FTB were superior to control in increasing the pD~2~ value.

  **3. Antitussive**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Yan et al., 2012 \[[@B90-ijms-20-01667]\]     In vivo      Micro powders                                                                   44 guinea pigs (citric acid induced cough model)                                Blank control: purified water, ig,qd; AZTB: 1.5 g/kg, ig, qd; FTB: 1.5 g/kg, ig, qd; Codeine phosphate: 0.02 g/kg, ig, qd                                                                                                5 min                                            FTB was superior to control in reduding the frequency of cough and prolonging the remission period.

  Yan et al., 2012 \[[@B89-ijms-20-01667]\]     In vivo      Micro powders                                                                   53 guinea pigs (citric acid induced cough model)                                Blank control: purified water, ig,qd; FTB: 1.5 g/kg, ig, qd; AZTB: 1.5 g/kg, ig, qd; WBBM: 1.5 g/kg, ig, qd; Codeine phosphate: 0.02 g/kg, ig, qd                                                                        5 min                                            FTB was superior to control in reduding the frequency of cough and prolonging the remission period.

  Guo, 2007 \[[@B27-ijms-20-01667]\]            In vivo      Aqueous extract                                                                 140 Kunming mice (ammonium hydroxide induced cough model)                       Blank control: NS, ig,qd; FTB: 0.026, 0.052, 0.104 g/kg respectively, ig, qd; Codeine phosphate: 0.03 g/kg, ig, qd                                                                                                       3 days                                           FTB harvested in all four places was superior to control in reduding the frequency of cough and prolonging the remission period.

  **4. Expectorant**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Yan et al., 2012 \[[@B89-ijms-20-01667]\]     In vivo      Fine powders                                                                    40 mice                                                                         Blank control: purified water, ig,qd; FTB: 2 g/kg, ig, qd; AZTB: 2 g/kg, ig, qd; WBBM: 2 g/kg, ig, qd; Ammonium chloride: 1 g/kg, ig, qd                                                                                 5 days                                           Fine powders of FTB was superior to control in reducing the amount of phlegm secretion.

  Wang et al., 1993 \[[@B86-ijms-20-01667]\]    In vivo      Alcohol extract                                                                 40 Wistar rats                                                                  Control: starch paste, 15 g/kg, ig,qd; FTB: 15 g/kg, ig, qd; CBM: 15 g/kg, ig, qd; WBM: 15 g/kg, ig, qd                                                                                                                  5 h                                              Alcohol extract of FTB was superior to control in reducing the amount of phlegm secretion.

  **5. Anti-inflammation**                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Kim et al., 2016 \[[@B33-ijms-20-01667]\]     In vitro     Peimine; Ebeiedine; Suchengbeisine                                              Human mucoepidermoid carcinoma cells NCI-H292                                   Peimine; Ebeiedine; Suchengbeisine                                                                                                                                                                                       24 h                                             Peimine, ebeiedine, or suchengbeisine was superior to control in decreasing the expression of MUC5AC mucin gene.

  Zhou et al., 2017 \[[@B73-ijms-20-01667]\]    In vitro     Puqiedine; Zhebeiresinol, 2-monopalmitin, N-demethylpuqietinone; Isoverticine   Human embryonic kidney cells HEK293                                             FTB 10, 3, 1 mg/mL respectively; Dexamethasone 10^−5^ mol/L                                                                                                                                                              6 h                                              Puqiedine, zhebeiresinol, 2-monopalmitin, n-demethylpuqietinone or isoverticine was superior to control in reducing the expression of NF-Κb level in cells.

  Xia et al., 2011 \[[@B87-ijms-20-01667]\]     In vivo      Aqueous extract                                                                 30 mice (CP/CPPS model)                                                         Blank control and blank normal: NS; FTB 0.1 mL/10 g, ig, qd                                                                                                                                                              7 days                                           Aqueous extract of FTB was superior to control in relieving the inflammation and over proliferation of fibroblasts of the prostate and reducing the serum level of nitric oxide in mice.

  Zhang et al., 1998 \[[@B93-ijms-20-01667]\]   In vivo      Alcohol extract                                                                 40 ICR mice (xylene induced ear swelling)                                       Blank control: Purified water, ig,qd; Ethenzamide 0.3 g/kg, ig,qd; FTB 0.8, 2.4 g/kg respectively, ig, qd                                                                                                                4 h                                              Alcohol extract of FTB was superior to control in releving the swelling of ear.

                                                In vivo      Alcohol extract                                                                 40 ICR mice (carrageenin induced foot plantar swelling)                         Blank control: Purified water, ig,qd; Ethenzamide 0.3 g/kg, ig,qd; FTB 0.8, 2.4 g/kg respectively, ig, qd                                                                                                                6 h                                              Alcohol extract of FTB was superior to control in releving the swelling of foot plantar.

  Xu et al., 2016 \[[@B88-ijms-20-01667]\]      In vitro     Peimine                                                                         Human Embryonic Kidney Cells HEK293                                             Peimine concentrations 1, 3 10, 30, 100, 300 μM                                                                                                                                                                          300 s                                            Peimine could inhibit the Nav 1.3 channel.

  **6. Pain suppression**                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  Zhang et al., 1998 \[[@B92-ijms-20-01667]\]   In vivo      Alcohol extract                                                                 44 ICR mice (acetic acid induced pain)                                          Blank control: Purified water, ig,qd; Ethenzamide 0.3 g/kg, ig,qd; FTB 0.8, 2.4 g/kg respectively, ig, qd                                                                                                                8 h                                              Alcohol extract of FTB was superior to control in reducing the frequency of mouse writhing.

                                                                                                                                             40 ICR mice (thermal stimulus pain)                                             Blank control: Purified water, ig,qd; Ethenzamide 0.3 g/kg, ig,qd; FTB 0.8, 2.4 g/kg respectively, ig, qd                                                                                                                3 h                                              Alcohol extract of FTB was superior to control in increasing the remission period of tail-flick latency.

  Xu et al., 2016 \[[@B88-ijms-20-01667]\]      In vitro     Peimine                                                                         Human Embryonic Kidney Cells HEK293                                             Peimine concentrations 1, 3 10, 30, 100, 300 μM                                                                                                                                                                          300 s                                            Peimine could inhibit the Nav 1.7 channel.

  **7. Antioxidation**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Ruan et al., 2016 \[[@B85-ijms-20-01667]\]    In vitro     Total alkaloids                                                                 DPPH radical; ABTS radical; FRAP reagent                                        DPPH: Total alkaloids 50 μL; ABTS: Total alkaloids 50 μL; FRAP: Total alkaloids 20 μL, control ethanol 20 μL                                                                                                             DPPH: 30 min; ABTS: Immediate; FRAP: Immediate   Total alkaloids in FTB have strong a antioxidative capacity evidence by the results of DPPH, ABTS and FRAP.

  Ma, 2014 \[[@B84-ijms-20-01667]\]             In vitro     polysaccharide                                                                  DPPH radical                                                                    polysaccharide 0.1, 0.2, 0.4, 0.6, 0.8, 1 mg/mL                                                                                                                                                                          30 min                                           Polysaccharide in FTB has strong antioxidative capacity evidence by the results of DPPH and absorption spectroscopy test.

  **8. Antiulcer**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  Zhang et al., 2018 \[[@B92-ijms-20-01667]\]   In vivo      Alcohol extract                                                                 90 SD rats (oral ulcer model)                                                   Blank model: NS; FTB 4, 2, 1 g/kg respectively, external, qid; Gui Lin Xi Gua Shuang, 1 g/kg, external, qid                                                                                                              6 days                                           Alcohol extract of FTB was superior to control in inhibiting oral ulcer.

                                                In vivo      Alcohol extract                                                                 120 ICR mice (gastric ulcer model)                                              Blank control: Purified water, ig,qd; Mepirizole 0.05 g/kg, ig,qd; FTB 0.8, 2.4 g/kg respectively, ig, qd;                                                                                                               2 h                                              Alcohol extract of FTB was superior to control in inhibiting gastric ulcer.

  **9. Anti-muscarinic**                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Zhou et al., 2006 \[[@B75-ijms-20-01667]\]    In vitro     Peimine; Peiminine; Puqietinone                                                 Human Embryonic Kidney Cells HEK293                                             Five alkaloids: 10μM (final concentration each); Negative control: carbachol, 0.3 μM (final concentration each); Positive control: Atropine 1 μM (final concentration each)                                              48 h                                             Peimine, peiminine or puqietinone was superior to control in raising the cAMP level in cells transfected with muscarinic M~2~ receptor.

  **10. Anti-thyroid**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Lin et al., 2010 \[[@B82-ijms-20-01667]\]     In vivo      Extract                                                                         180 SD rats; 60 SPF mice (hyperthyroidism model)                                Blank control and blank model: NS, ig, qd; Tapazole 0.02 g/kg, ig, qd; FTB 3, 1.5, 0.75 g/kg respectively, ig, qd                                                                                                        14 days                                          FTB was superior to control in reducing the serum level of T~3~, T~4~, cAMP, cGMP and raising the abilities of hypoxia tolerance.

  **11. Regulation of blood rheology**                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Jiang et al., 2002 \[[@B78-ijms-20-01667]\]   In vivo      Aqueous extract                                                                 50 SD rats                                                                      Blank control: Purified water, ig,qd; FTB 1 mL respectively, ig, qd                                                                                                                                                      1 week                                           Aqueous extract of FTB was superior to control in reducing the whole blood viscosity, restricting the trythrocyte aggregation and raising the erythrocyte deformability.

  **12. Anti-diarrhea**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  Zhang et al., 1998 \[[@B93-ijms-20-01667]\]   In vivo      Alcohol extract                                                                 40 ICR mice (castor oil induced diarrhea); 40 ICR mice (FXY induced diarrhea)   Blank control: Purified water, ig,qd; Ethenzamide 0.3 g/kg, ig,qd; FTB 0.8, 2.4 g/kg respectively, ig, qd                                                                                                                8 h                                              Alcohol extract of FTB was superior to control in reducing the frequency of diarrhea.

  **13. Neuroprotection**                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  Suh et al., 2018 \[[@B8-ijms-20-01667]\]      In vitro     Frithunbol B; Ebeiedinone; 3β-hydroxy-5α-jervanin-12-en-6-one; Suchengbeisine   lipopolysaccharide-activated BV-2 cells; C6 glioma cells                        NO study: 100 ng/mL isolates; NGF study: 20 μM isolates                                                                                                                                                                  24 h                                             Frithunbol B, ebeiedinone, and suchengbeisine significantly reduce the nitric oxide level, compared to control; 3β-hydroxy-5α-jervanin-12-en-6 -one was superior to control in increasing the nerve growth factor level.
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Note: ABTS: 2,2′-azino-bis (3-ethylbenzothiazoline-6-sulphonic acid); AZTB: An zi bei mu, Fritillaria unibracteata Hsiao et K. C. Hsia; CBM: Chuan bei mu, Fritillariae Cirrhosae Bulbus; CMC-Na: Sodium carboxyl methyl cellulose; CP/CPPS: Chronic prostatitis/chronic pelvic pain syndrome; DDP: Cisplatin; DPPH: 2,2-diphenyl-1-picrylhydrazyl; FRAP: Ferric reducing capacity; FTB: Fritillariae Thunbergii Bulbus, Zhe bei mu; FXY: Fan xie ye, Sennae Folium; FZ: Fu zi, Aconiti Radix Lateralis Praeparata; ICR: Institute of Cancer Research; NF-κB: Nuclear factor-κB; NGF: Nerve growth factor; NO: Nitric oxide; NS: Normal saline; P-gp: P-glycoprotein; SD: Sprague Dawley; SPF: Specific-pathogen-free; WBM: Wan bei mu, Fritillaria anhuiensis S.C.Chen et S.P.Yin; WBBM: Wa bu bei mu, Fritillaria unibracteata Hsiaoet K. C. Hsia var. wabuensis (S. Y. Tang et S. C. Yue) Z. D. Liu, S. Wang et S.C. Chen.
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Pharmacokinetics of peimine (A1) and peiminine (A2) and peimisine (A9) in Fritillariae Thunbergii Bulbus.

  Included Studies                             Study Type   Methods                        Animals                            Interventions              T~1/2~ (h)    T~max~ (h)    CL/F (L/h/kg)   V/F (L/kg)      C~max~ (μg/L)   AUC~0-t~ (μg h/L)   AUC~0-∞~ (μg h/L)
  -------------------------------------------- ------------ ------------------------------ ---------------------------------- -------------------------- ------------- ------------- --------------- --------------- --------------- ------------------- -------------------
  Chen et al., 2011 \[[@B76-ijms-20-01667]\]   In vivo      LC-MS-MS; DAS 2.0 package      12 female SD rats                  Peimine, 4.25 g/kg, ig     4.8 ± 0.8     1.5 ± 0.6     119.6 ± 40.1    854.8 ± 363.9   43.2 ± 5.4      N/A                 260.5 ± 119.8
                                                                                                                              Peiminine, 4.25 g/kg, ig   6.6 ± 3.2     4.5 ± 1.9     34.1 ± 4.8      321.1 ± 155.4   57.6 ± 23.0     N/A                 618.3 ± 94.8
  Chen et al., 2013 \[[@B77-ijms-20-01667]\]   In vivo      LC-MS-MS; DAS 2.0 package      6 female SD rats                   Peimine, 4.25 g/kg, ig     4.2 ± 2.0     1.5 ± 0.7     128.9 ± 32.6    781.3 ± 305.6   43.7 ± 22.7     214.2 ± 84.6        214.3 ± 84.5
                                                                                                                              Peiminine, 4.25 g/kg, ig   3.4 ± 1.7     2.8 ± 0.9     36.3 ± 15.8     268.8 ± 163.9   64.2 ± 40.0     571.0 ± 243.4       571.1 ± 243.9
                                                                                           6 SD male rats                     Peimine, 4.25 g/kg, ig     6.2 ± 1.9     2.9 ± 1.7     41.5 ± 20.1     374.1 ± 186.2   57.6 ± 21.6     662.4 ± 277.9       665.3 ± 213.3
                                                                                                                              Peiminine, 4.25 g/kg, ig   5.1 ± 1.4     3.0 ± 1.4     10.5 ± 2.6      92.2 ± 55.1     135.6 ± 40.2    1965.5 ± 433.3      1969.6 ± 433.5
  Tong, 2016 \[[@B49-ijms-20-01667]\]          In vivo      UHPLC-MS/MS; DAS 2.0 package   6 SD male rats; 6 female SD rats   Peimine, 0.45 g/kg, ig     2.7 ± 0.5     0.5 ± 0.2     N/A             40.8 ± 17.6     3.7 ± 0.9       10.5 ± 1.7          10.6 ± 1.7
  Peiminine, 0.45 g/kg, ig                     1.9 ± 0.8    0.7 ± 0.2                      N/A                                9.6 ± 5.0                  12.6 ± 2.0    37.1 ± 13.7   37.1 ± 13.8                                                         
  Peimisine, 0.45 g/kg, ig                     4.0 ± 1.0    0.8 ± 0.3                      N/A                                12.1 ± 4. 9                1.2 ± 0.2     4.6 ± 2.0     4.7 ± 2.1                                                           
  Xu et al., 2017 \[[@B59-ijms-20-01667]\]     In vivo      UHPLC-MS/MS; DAS 2.0 package   6 male SD rats                     Peimine, 20 g/kg, ig       2.3 ±0.8      2.8 ± 1.4     N/A             N/A             74.7 ± 18.2     474.5 ± 143.4       N/A
                                                                                                                              Peimisine, 20 g/kg, ig     2.68 ± 0.78   3.3 ± 1.1     N/A             N/A             15.1 ± 2.0      120.7 ± 31.3        N/A

Note: DAS 2.0: Drug and Statistic 2.0; N/A: Not applicable; SD: Sprague Dawley.
